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GENERAL INTRODUCTION 
 
 
 
 
Alzheimer’s disease (AD), first described by Aloϊs Alzheimer more than a century ago, is 
the most common type of dementia in the elderly. It is characterized by memory loss in 
early stages, and severe cognitive impairment and deterioration of global cognitive 
functions, such as apraxia, aphasia, agnosia, visuo-spatial difficulties and executive 
functions, later on. The disease has an enormous impact on patients and their caregivers, 
but also on society. To date, it is the single most costly disease in the Netherlands. In 
subjects aged over 65 prevalence rates for dementia vary between 5.9 and 9.4%,1 while 
54% of all patients with dementia suffered from AD.2 The prevalence of AD increases with 
age: 0.6% of people aged 65-69 show symptoms of AD, whilst 22.2% of people aged 90 
and over are diagnosed with AD.2 Despite extensive research the etiology of AD is still 
not known.  
The clinical diagnosis AD relies on clinical criteria, supported by additional testing, 
such as neuropsychological assessment, laboratory tests and brain imaging. The 
diagnostic criteria formulated by an international working group, the National Institute of 
Neurological and Communicating Disorders and Stroke and the Alzheimer’s Disease and 
Related Disorders Association (NINCDS-ADRDA) (table 1)3 are widely used. Within the 
NINCDS-ADRDA criteria, at least two cognitive domains should be affected in order to 
fulfill the diagnostic criteria for AD.  
It is thought that AD is preceded by a transitional phase, usually referred to as 
mild cognitive impairment (MCI). MCI is a clinical entity in which subjects experience 
cognitive decline without interference with activities of daily living. Petersen et al.4 
proposed criteria that have been used for research and clinical trials (table 2). MCI 
patients have an increased risk of developing AD (about 10-15% per year).5,6 However, 
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not all subjects will develop AD. Indeed, some patients develop other types of dementia, 
whilst others remain stable and some even improve after some time. Recently, new 
criteria for the diagnosis of AD were proposed, which allows diagnosis related to 
neuropatholocial changes in AD, based on the use of biomarkers of AD.7,8 According to 
this new classification, patients with MCI, i.e. episodic memory loss in which biomarker 
evidence from cerebrospinal fluid or imaging is supportive of the presence of AD 
pathological changes, are considered to have “prodromal AD”.  
 
 
Neuropathology 
The definite diagnosis of AD can be made only after death using post-mortem 
neuropathological examination. Macroscopic AD brains show cerebral atrophy. On 
microscopic examination extracellular plaques and intracellular neurofibrillar tangles 
consisting of hyperphosphorylated tau are present. The extracellular plaques consist 
largely of amyloid beta peptide (Aβ). Aβ is a peptide that is produced by cleavage of the 
larger protein amyloid β precursor protein (APP) by β- or γ-secretase. Neurofibrillary 
tangles (NFT) and neuropil threads show a characteristic distribution pattern following a 
predictable sequence over the course of the disease.9 In the preclinical stage (stage I) 
NFT start in transentorhinal areas and spread into entorhinal cortex and hippocampus 
(stage II). In stages III and IV, neurofibrillary pathology increases in entorhinal cortex and 
hippocampus, and spreads to the adjacent inferior temporal cortex and amygdala. In 
more advanced stages V and VI, neuropathological changes spread to neocortical 
association cortex and other brain regions. Probably amyloid deposition also follows a 
predictable topographical sequence. In the preclinical stage (1-3) amyloid deposits 
appear first in neocortex and subsequently in allocortex, diencephalon and basal 
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forebrain. In AD midbrain, lower brainstem (stage 4) and cerebellum (stage 5) are 
involved as well.10 Distribution and density of neurofibrillary tangles and amyloid plaques 
was studied in subjects whose premortem cognitive status was assessed and it appeared 
that deposition of amyloid plaques accelerates age-related formation of tangles.11 
Interestingly, the amount of neurofibrillary tangles may correlate better with the degree of 
cognitive impairment than plaque burden.12 
Postmortem studies indicate that besides plaques and tangles, activated 
microglia, the macrophages of the brain, are invariably found in AD. Indeed, microglia 
activation has been shown to be associated with senile plaques and neurofibrillary 
tangles13-15 and may be present years before symptoms become apparent clinically.16 
Clusters of activated microglia were not found in non-fibrillar Aβ plaques that lack a 
central core, but occurred most prominently in the vicinity of immunoreactive fibrillar Aβ 
plaques, suggesting that they might be involved in the deposition of Aβ.17,18 These 
findings resulted in the concept that Aβ peptide itself can induce a local inflammatory 
response, in which fibrillar Aβ is able to activate the classical complement pathway, 
resulting in the attraction and activation of microglial cells. Microglial cells subsequently 
produce multiple pro-inflammatory and neurotoxic factors which can reinforce the 
pathological cascade by a positive feed back loop.19  
The function of microglial activation in the pathogenesis of AD is still unknown and 
further studies are warranted. In vivo visualisation of microglia activation with positron 
emission tomography (PET) can be used to further unravel the role of activated microglia 
in AD.  
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Visualising microglial activation in vivo in AD 
PET is a method that makes it possible to visualise and quantify activated microglia in 
vivo. In general, PET utilizes radiopharmaceuticals that are labelled with a positron 
emitting radionuclide, such as 11C. Positron emitting radionuclides decay by emission of a 
positron, which after travelling a few mm in tissue, combines with an electron. In the 
subsequent annihilation process of the masses of both particles (positron and electron) 
are converted into two photons of 511 keV that are emitted into essentially opposite 
directions. PET is based on the coincidence detection of these two photons. From the 
collected coincidence detections (emission data) a three dimensional image can be 
reconstructed, showing uptake and distribution of the labelled molecule in the organ of 
interest (brain) as a function of time. Using pharmacokinetic analysis, quantitative 
measures of radioligand binding across the brain can be derived. Tracer pharmacokinetic 
models are based on compartments that describe the behaviour of the tracer in the 
tissue. In addition, an input function is required that describes the delivery of the tracer to 
the tissue over time. The gold standard input function is a metabolite corrected arterial 
plasma curve. It is, however, rather labour intensive to collect arterial samples and to 
derive parent tracer fraction. In addition, and more importantly, arterial sampling is 
invasive and painfull for the patient. If a reference tissue (devoid of specific binding) is 
available, arterial sampling can be avoided, enhancing clinical applicability of PET 
studies.  
(R)-[11C]PK11195 (1-(2-chlorophenyl)-N-methyl-N-1(1-methylpropyl)-3-
isoquinolinecarboxamide) is a PET tracer of microglial activation. (R)-PK11195 binds to 
the peripheral benzodiazepine binding site (PBR), recently renamed to translocator 
protein (TSPO)20, which is expressed by cells of the mononuclear macrophage lineage 
and is markedly increased in activated microglia. Using (R)-[11C]PK11195 and PET, 
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microglial activation has already been demonstrated in several neurodegenerative 
diseases (for a review see Venneti et al.21).  
In AD, several studies assessing microglia activation using labelled PK11195 have 
been published using both PET22-24 and single photon emission computed tomography.25 
Using a racemic mixture of [11C]PK11195, increased binding could not be demonstrated 
in eight AD patients compared with one healthy control subject and seven patients with 
glioma.22,26 Cagnin et al.23 performed the first study using the pure (R) enantiomer of 
PK11195, which has a higher affinity for TSPO than the racemic mixture. In AD, 
increased binding was found in several brain areas of eight patients with AD and a single 
MCI subject.23 This has been corroborated recently in 11 AD patients, showing increased 
(R)-[11C]PK11195 binding compared to controls.27 More recently, two studies have been 
published describing (R)-[11C]PK11195 binding in MCI24,28, showing either increased28 or 
unchanged24 (R)-[11C]PK11195 binding in MCI. These inconsistent results might be 
explained by differences in sample size, scanning techniques or methodology and further 
studies are warranted. This is important, as imaging microglial activation with PET might 
provide insight in the involvement of microglial activation in the pathogenesis of AD. 
Quantitative analysis is mandatory from the perspective of potential interventions that 
attempt to prevent the disease or slow down the rate of disease progression. The first aim 
of this thesis was to quantify microglial activation in prodromal AD and AD dementia 
patients using (R)-[11C]PK11195 and PET.   
 
Inflammatory proteins in AD 
Apart from microglia activation, many inflammation related proteins are upregulated, such 
as complement factors, acute-phase proteins and pro-inflammatory cytokines, and all 
have been found to be associated with affected brain areas in AD.29 Several of these 
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factors promote neurodegenerative mechanisms, whereas others may be 
neuroprotective. Serum amyloid P component (SAP) is a glycoprotein that binds to a 
variety of ligands including Aβ and, in turn, leads to binding of complement factor C1q, 
which initiates activation of the classical pathway of the complement system mentioned 
above. Activated microglia and astrocytes that accumulate in Aβ plaques express 
neuroinflammatory proteins, such as interleukin-1 (IL-1), interleukin-6 (IL-6), or tumour 
necrosis factor α, as well as acute phase proteins, C-reactive protein (CRP) and α1-
antichymotrypsin (ACT).29,30  ACT is co-localized with Aβ deposits in AD brain and is 
thought to play a role in their formation. Overexpression of IL-6, a cytokine that mediates 
immune responses, is usually detrimental, as it induces lymphocyte activation, antibody 
synthesis and acute phase proteins, such as C-reactive protein. In animal models 
neuropathological changes, indicative of a chronic inflammatory response, have been 
correlated with clinical deficits. Beneficial effects of IL-6, however, are also known. For 
example, there is evidence that IL-6 may have anti-inflammatory properties (for a review 
about inflammatory mediators see Akiyama et al.29).  
Clinical studies on peripheral inflammatory markers in AD have produced 
conflicting results. Only a few studies on CRP in serum have been published31, whereas 
several studies regarding IL-6 and ACT have been performed. Some cerebrospinal fluid 
(CSF) studies on IL-6 and ACT have shown no differences between controls and AD 
patients32-34, while others found increased IL-6 or ACT levels in AD compared with control 
subjects.35,36 Recently, a few longitudinal population based studies have shown an 
association between inflammatory markers (CRP, IL-6, ACT) and cognitive decline many 
years before onset of dementia.37-39 The second aim of this thesis was to investigate 
whether the inflammation related proteins SAP, CRP, IL-6 and ACT are indeed present in 
earlier stages of AD in both CSF and serum. 
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Outline of this thesis 
The general objective of this thesis was to explore several aspects of inflammation in 
aging and (the early stages of) AD, in order to provide further insight into the 
pathogenesis of AD. Two approaches were used: measurements of inflammatory 
markers in serum and CSF, and in vivo imaging of microglia activation using PET.  
 
First, in chapter 2.1, involvement of the inflammatory markers IL-6, ACT and CRP early 
in the pathological process underlying AD in patients with MCI and AD will be assessed. 
IL-6, ACT and CRP levels were measured in serum and CSF and related to their 
amyloidβ-42 (Aβ42)/tau risk profiles. In chapter 2.2 it was investigated whether SAP 
levels in CSF or serum reflect involvement of SAP at various stages of AD 
pathophysiology and can be used to identify incipient AD among patients with MCI. 
 
Chapter three evaluates several methods for quantification of (R)-[11C]PK11195 binding. 
In chapter 3.1, the optimal parametric method for quantification of (R)-[11C]PK11195 
binding at the voxel level was determined. Several parametric methods using both arterial 
plasma and reference tissue inputs were evaluated using both simulations and clinical 
data. In chapter 3.2 the performance of (simplified) plasma input and reference tissue 
parametric methods on the outcome of statistical parametric mapping (SPM) analyses of 
(R)-[11C]PK11195 binding was assessed in young and elderly healthy subjects. 
 
Next, in chapter 4, we describe microglial activation in normal aging and in MCI, i.e. 
prodromal AD and AD dementia patients, using (R)-[11C]PK11195 and PET. In chapter 
4.1 the effects of aging on (R)-[11C]PK11195 binding was examined in order to establish 
whether normal aging is associated with microglial activation. Chapter 4.2, describes 
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specific binding of (R)-[11C]PK11195 in prodromal AD and AD dementia patients. The 
purpose of this study was to determine extent and distribution of activated microglia as 
reflected by (R)-[11C]PK11195 binding in relatively large cohorts of AD dementia and 
prodromal AD patients. A second aim was to establish whether presence of (R)-
[11C]PK11195 binding in prodromal AD is associated with progression to AD dementia.  
 
Finally, in chapter 5, the main findings of this thesis are summarised, followed by a 
general discussion and future perspectives.  
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Table 1. NINCDS-ADRDA criteria for probable Alzheimer’s disease3 
1. Dementia established by clinical examination and confirmed by neuropsychological tests 
2. Deficits in two or more areas of cognition, including memory impairment 
3. Progressive worsening of memory and other cognitive functions 
4. No disturbances of consciousness 
5. Onset between ages 40 and 90 
6. Absence of systemic disorders or other brain disease that in and of themselves could account for 
the progressive deficits in memory and cognition 
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Table 2. Criteria for amnestic Mild Cognitive Impairment by Petersen et al.4 
1. Memory complaint, preferably corroborated by an informant 
2. Objective memory impairment for age and education, at neuropsychological testing 
3. Normal general cognition 
4. Preserved activities of daily living 
5. No dementia 
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Abstract 
Objective: The aim of this study was to demonstrate the involvement of the inflammatory 
proteins IL-6, ACT and CRP early in the pathology process of AD in patients with Mild 
Cognitive Impairment (MCI) and AD.  
Methods: IL-6, ACT, CRP, Aβ42, phospho-tau (p-tau) and total tau concentrations in 
serum and CSF of 145 patients with probable AD and 67 patients with MCI were 
measured by sandwich ELISA. MCI patients were characterized as high- respectively 
low-risk MCI according to their Aβ42/tau risk profile.  
Results: CSF and serum CRP levels were significantly higher in MCI compared to AD 
patients after adjustment for age, ApoE ε4 genotype and cardiovascular diseases 
(p<0.01). This difference remained present in patients with a low-risk biomarker profile for 
AD after adjustment for abovementioned covariates. CSF IL-6 levels were also 
significantly higher in MCI patients with a low-risk CSF profile.  
Conclusions: These findings suggest that inflammatory processes might be involved in 
early stages of AD, even before Aβ and tau changes are present in CSF of MCI patients.  
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Introduction 
Immunopathological and experimental evidence supports the hypothesis that 
inflammatory mechanisms are involved in the aetiology of Alzheimer’s disease (AD), even 
before fibrillar amyloid deposits are present.1,2 
Activated microglia and astrocytes that accumulate in amyloid beta (Aβ) plaques express 
pro-inflammatory cytokines, such as interleukin-1 (IL-1), interleukin-6 (IL-6), or tumour 
necrosis factor α, as well as acute phase proteins C-reactive protein (CRP) and α1-
antichymotrypsin (ACT).1,3 Microglial activation and clustering most prominently occur in 
Aβ deposits that have bound and accumulated complement activation products and other 
amyloid associated factors, and precedes the neurodegenerative changes in AD 
neocortex.2 
 To date, different inflammatory markers have been studied in CSF and serum of 
AD patients with conflicting results (for a review see Teunissen et al.4). Only a few studies 
on CRP in serum have been published,5 whereas several studies regarding IL-6 and ACT 
have been performed. Some CSF studies on IL-6 and ACT demonstrated no differences 
between controls and AD patients,6-8 while others found increased IL-6 or ACT levels in 
AD compared to control subjects.9,10 The observed differences might partly be explained 
by differences in the study population such as inclusion criteria or the number of subjects. 
In addition, an association between plasma levels of the inflammatory markers CRP, IL-6 
and ACT and cognitive decline, many years before onset of dementia, has been 
demonstrated in a few longitudinal population-based studies.11-13  
To study  the role of inflammation in the preclinical stage of AD further, we selected a 
large cohort of patients with mild cognitive impairment (MCI), which is considered to be a 
preclinical stage of AD.14  Follow-up studies show a conversion rate to AD of 12 – 41 % 
per year in MCI patients.14-16 The aim of the present study was to examine the 
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involvement of inflammatory markers early in the pathology process of AD. Therefore, we 
studied the inflammatory markers CRP, IL-6 and ACT in both serum and CSF in a cohort 
of established MCI and AD patients. 
 
Materials and methods 
Patients. Between November 2000 and April 2004 67 patients with MCI and 145 patients 
with probable AD were enrolled at the Alzheimer Center of the VU University Medical 
Center (VUMC), Amsterdam. Diagnoses of MCI and probable AD were according to 
Petersen14 and NINCDS-ADRDA criteria,17 respectively. MCI patients, were divided in 
MCI patients at high or low risk for AD, according to their Aβ42 and tau levels in CSF.18,19 
The degree of cognitive impairment was evaluated by Mini Mental State Examination 
(MMSE).20 Patients had no symptoms or signs of intercurrent infectious conditions. The 
ethical review board of the VUMC approved the study protocol and all subjects (and in 
case of AD also a relative) gave informed consent. 
CSF analysis. CSF samples were obtained as described previously.19 Levels of IL-6,  in 
serum and CSF samples were determined with a commercial sandwich ELISA (Pelikine  
Sanquin, Amsterdam, The Netherlands). CRP and ACT were determined with in house 
methods with commercial available antisera (DAKO, A/S Denmark). In case of ACT, an in 
house monoclonal antibody detecting all structural forms of ACT was used as catching 
antibody. CSF Aβ42, CSF T-tau, and CSF P-tau-181 were measured as reported 
previously.19 Serum and CSF samples were tested in the same run. See supplementary 
data for intra-inter assay variations and detection limits.  
Possible confounders. Age, sex, apolipoprotein E ε4 (ApoE ε4), diabetes mellitus, 
cardiovascular diseases and use of non-steroidal anti-inflammatory drugs (NSAIDS) may 
influence expression, and thus are possible confounders when investigating the 
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association of inflammatory markers to dementia. For the analyses we only selected 
those factors that showed significant differences between MCI and AD patients as 
covariates (p < 0.20). Additional analyses were then performed including the 
abovementioned covariates as well as extensive white matter lesions (Fazekas score = 
321) or infarcts as detected by MRI22. ApoE genotyping was performed with the Light 
Cycler ApoE mutation detection method (Roche Diagnostics GmbH, Mannheim, 
Germany). Data on use of NSAIDS, cardiovascular diseases and diabetes mellitus were 
based on medical history and/or medication.  
Statistical analysis. Data analysis was performed with the SPSS software package 
(version 11.5 for Windows SPSS, Chicago Il). Spearman rank correlation coefficients (r) 
between the inflammatory markers were reported. All inflammatory markers were log-
transformed before analysis. Analysis of covariance (ANCOVA), with age, APOE ε4 and 
cardiovascular diseases as covariates, was used to determine differences between MCI 
and AD patients.  
 
Results 
Spearman rank correlations between CSF and serum inflammatory markers were 0.16 for 
IL-6, 0.85 for CRP, and 0.36 for ACT. In CSF, correlations between IL-6 and CRP were 
0.20, between IL-6 and ACT 0.16, and between CRP and ACT 0.38. In serum, 
correlations between IL-6 and CRP were 0.53, between IL-6 and ACT 0.11, and between 
CRP and ACT 0.16.  
To assess the levels of cytokines in patients with different Aβ42/tau biomarker profiles 
(high-risk and low-risk CSF profiles), MCI patients were stratified according to previously 
published cut-off values for CSF Aβ42, T-tau, and P-tau-181.18,19 High-risk CSF profile 
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was defined as CSF with values of Aβ42 < 495 pg/mL and T-tau > 356 pg/mL or P-tau > 
54 pg/mL.  
 Clinical characteristics and inflammatory marker levels of patients included in this 
study are summarized in Table 1. Of the MCI patients, 52.3 % had a high-risk CSF profile 
compared with 73.1% of the AD patients (p < 0.01). Median MMSE scores were 26 for 
MCI and 21 for AD patients (p < 0.001). MCI patients had a significantly lower prevalence 
of ApoE ε4 genotype (p = 0.001), and a higher prevalence of cardiovascular diseases (p 
< 0.01). Gender, diabetes mellitus or use of NSAIDs were similar between MCI and AD 
patients. The low-risk MCI cohort had a significantly lower prevalence of ApoE ε4 
compared to high-risk MCI and AD patients, and the high-risk MCI cohort had a 
significantly higher incidence of cardiovascular diseases compared to AD patients.  
In the total sample, both CSF and serum CRP levels were significantly higher in MCI 
compared to AD patients (p < 0.01).  For ACT and IL-6, neither CSF nor serum levels 
differed significantly between MCI and AD patients (ACT: p = 0.38 and 0.23; IL-6: p = 
0.13 and 0.61 in CSF respectively serum). The observed differences for CRP between 
MCI and AD patients remained significant after adjustment for age, ApoE ε4  and 
cardiovascular diseases (p = 0.02 for CSF and serum).  
Both high- and low-risk MCI patients demonstrated higher levels of CRP in CSF and 
serum compared to AD patients; differences were statistically significant between low-risk 
MCI and AD patients (p = 0.03 for CSF and 0.05 for serum CRP). No differences in CSF 
or serum CRP levels between high-risk MCI and AD patients or high- and low-risk MCI 
could be demonstrated after adjustment for abovementioned covariates. CSF IL-6 was 
significantly higher for low-risk MCI compared to AD patients (p = 0.03), but serum IL-6 
did not significantly differ between the patient groups. CSF or serum ACT levels were 
similar in MCI patients with either risk profile and in AD patients.  
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When analyses were repeated with severe white matter lesions (a Fazekas score of 321) 
or brain infarcts on MRI as additional covariates, CSF and serum CRP levels were 
significantly higher in low-risk MCI compared to AD patients (p = 0.01 and p = 0.03 
respectively). Differences in IL-6 levels in CSF between low-risk MCI and AD patients 
remained significant after additional correction for white matter lesions and brain infarcts 
(p = 0.05). No significant differences were found for ACT levels.  
 
Discussion 
In the present study significantly higher CRP levels were observed in both CSF and 
serum of MCI cases compared to AD patients. This was seen in the MCI group as a 
whole, as well as in subcohorts of MCI patients with a high- and low-risk profile. After 
adjustment for age, ApoE ε4, cardiovascular diseases, white matter lesions and brain 
infarcts, this significant difference persisted only in the low-risk MCI subgroup. For IL-6 
and ACT no differences between MCI and AD patients were found in the total group. 
However, IL-6 levels in CSF were significantly higher in the low-risk MCI subgroup 
compared to AD patients after adjustment for abovementioned covariates.  
Our data on increased CRP levels in serum in MCI patients support findings from several 
population-based studies11-13,23,24 on inflammatory markers and cognitive decline. In the 
Honolulu-Asia Aging study an increased risk for either AD or vascular dementia was 
found with increased CRP even after 25 years.12 In the Rotterdam Scan study higher 
levels of CRP were found not to be associated with dementia but with white matter 
lesions.22 However, our findings of higher CRP concentrations in the low-risk MCI 
subsample, after adjusting for cerebrovascular factors, suggest that inflammatory proteins 
are related to cognitive decline, independent of white matter lesions. No differences in 
inflammatory indexes,25 corrected for albumin, or in albumin quotient26 between AD and 
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MCI patients, corrected for age, were found, suggesting that blood-CSF barrier 
permeability is not different between the patient groups (data not shown). ACT, IL-61 as 
well as CRP3 can be locally produced in the brain and expression is upregulated in AD 
affected brain areas. This suggests that the levels of inflammatory proteins measured in 
CSF may result from local production, although we cannot exclude diffusion across the 
blood-CSF barrier. 
Several clinical studies demonstrated increased IL-6 or ACT levels in serum5,27-29 and 
CSF9,10,30 in AD patients compared to controls, although in others no differences could be 
demonstrated.6,22 However, to our knowledge, no studies investigating levels of the 
inflammatory markers CRP, IL-6 and ACT in serum and CSF in a clinical cohort of MCI 
patients have been performed, making our study difficult to compare with previous 
studies. A major strength of the present study is the combination of inflammatory markers 
in serum and CSF and selection of two relatively large subsamples of MCI patients 
according to their CSF Aβ42/tau profiles in addition to a large sample of AD patients. The 
MCI patients were diagnosed using the Petersen criteria14 and therefore differences in 
clinical characteristics between both high- and low-risk MCI patients are not likely. A 
limitation of our study might be the absence of a healthy control population, although this 
is often the case in CSF studies for obvious reasons. 
In conclusion, the observed increase in CRP and IL-6 levels in MCI patients with a low-
risk biomarker profile for AD, as opposed to AD, supports the hypothesis that 
inflammation is a relatively early event in the pathological cascade of the disease.1 Our 
data suggest that in patients with low-risk MCI, i.e. before plaques and tangles are 
reflected in changed CSF Aβ42/tau profiles, inflammatory processes are even more 
pronounced than in later stages.  
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Supplementary data   
 
CSF analysis 
For CRP-high sensitivity we used a semi-automated in house method with commercially 
available antisera (DAKO, A/S Denmark) with an intra- and interassay variation at two 
levels of 3.9% and 8.1%. For IL-6 a commercially available ELISA (Pelikine  Sanquin, 
Amsterdam, The Netherlands) was used with a intra-inter assay variation of 4.6% and 
8.1%. Serum and CSF levels of ACT were determined in a sandwich ELISA detecting all 
structural forms of ACT. The IgG fraction of an ACT-specific monoclonal anti-ACT (AC3, 
which detects native, complexed as well as inactivated ACT) was coated onto 96-well 
ELISA plates (Costar highbinding, USA) in a 50 mM carbonate buffer (pH 9.6) at room 
temperature for 18 hours. After two washes with PBS, the residual binding sites were 
blocked with High Performance Elisa buffer (HPE, Sanquin, Amsterdam) for one hour. 
After washing with PBS 0.05% Tween, samples, standards and controls  (diluted in HPE) 
were incubated in the wells for one hour at room temperature. Bound ACT was detected 
after subsequent incubations with biotinylated (ECL Protein Biotinylation Module, 
Amersham Biosciences, UK) Polyclonal Rabbit Anti-Human Alpha-1-Antichymotrypsin 
(DakoCytomation, Denmark) for one hour and with peroxidase-labelled streptavidin 
(Amersham Biosciences, UK) for 30 minutes. Washing in between incubation steps was 
with PBS containing 0.05% Tween 20. For colour development 3,5,3’,5’-
tetramethylbenzidine (TMB; Sigma, Germany) at a concentration of 100 µg/mL in 0.11 M 
sodium acetate (pH 5.5) containing 0.003% H2O2 (100 µL final volume) was used as a 
substrate. The substrate reaction was stopped by adding 2 M H2SO4. Absorption at 450 
nm was then determined in a Rainbow microtiterplate  reader (SLT, Austria) corrected for 
background (OD540). The ACT concentrations were calculated with MultiCalc (Wallac, 
   
 35 
Finland) software. The intra-inter assay variation of variation at two levels were 7.0% and 
10.2% respectively. The detection levels were 0.13 ug/L for CRP-hs, 0.32 pg/ml for IL-6 
and 0.098 μg/L for ACT.  
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Table 1. Clinical characteristics of MCI, total group and separately for those with high and low risk AD profile*, and AD patients 
 
 
Total MCI 
(N=67) 
 
MCI, low risk AD  
(N=31) 
MCI, high risk AD  
(N=34) 
AD  
(N=145) 
P - values 
Age, yr 70.1 (63.5-76.1) 70.3 (62.8-78.2) 69.8 (63.5-73.2) 66.5 (58.2-73.6) a,c 
Men, % (n) 50.7 (34) 51.6 (16) 50.0 (17) 46.2 (67)  
MMSE 
**
 26 (24.8-28) 26.5 (25-28) 26 (23-27) 21 (18-25) a,b,c 
ApoE ε4, % (n)
***
 52.2 (35) 29.0 (9) 73.5 (25) 76.2 (96) a,b,d 
Cardiovascular diseases, % (n)
****
 59.1 (39) 56.7 (17) 58.8 (20) 38.9 (56) a,c 
Diabetes mellitus, % (n) 6.0 (4) 6.5 (2) 5.9 (2) 4.1 (6)  
NSAIDs use, % (n) 6.0 (4) 6.5 (2) 5.9 (2) 6.2 (9)  
CSF      
   Aβ42, pg/mL 441 (371-657.8) 660 (540-896) 396 (354.8-433.8) 383 (290-477.5) b,d 
   T-tau, pg/mL 529 (342.5-784.5) 331 (260-550) 668 (489.8-907.5) 685 (440-955) b,d 
   P-tau, pg/mL 71 (49-101) 51(39-79) 87.5 (69-111.3) 83 (59-112.5) b,d 
   IL-6, pg/mL 2.09 (1.64-2.71) 2.27 (1.84-3.95) 2.09 (1.51-2.29) 1.96 (1.53-2.49) b  
   CRP, μg/L 3.18 (1.90-7.12) 4.17 (2.24-13.48) 3.17 (1.88-5.96) 2.25 (1.03-4.90) a,b  
   ACT, mg/L 0.30 (0.22-0.46) 0.28 (0.23-0.47) 0.31 (0.20-0.46) 0.31 (0.23-0.38)  
Serum      
   IL-6, pg/mL 1.64 (1.13-2.14) 1.61 (1.09-2.27) 1.75 (1.21-2.15) 1.41 (0.98-2.32)  
   CRP, mg/L 1.56 (0.72-3.24) 1.92 (0.77-3.73) 1.38 (0.83-2.55) 0.92 (0.46-2.03) a, b  
   ACT, mg/L 39.5 (30.4-49.3) 39.5 (30.7-47.9) 40.2 (30.5-53.2) 40.7 (36.4-48.0)  
Values are expressed as medians (25
th
 to 75
th
 percentile), unless otherwise indicated. 
*
 High risk AD profile based on plaques/tangles profile, defined as Ab42 <= 494 pg/mL and (P-tau > 54 pg/mL or T-tau > 356). N=2 cases with missing values on Aβ or tau. 
**
 N=6 cases with missing values. 
***
 N=19 cases with missing values.
 ****
 N=2 cases with missing values. 
P-values: adjusted for age, cardiovascular diseases and APOE.  P-values ≤ 0.05, unless otherwise indicated. a = total MCI versus AD; b = MCI, low risk, versus AD; c = MCI, 
high risk, versus AD; d = MCI low risk versus MCI high risk. 
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Abstract 
Background: Serum-Amyloid-P-component (SAP), present in amyloid-β (Aβ) plaques in 
Alzheimer’s disease (AD), may protect Aβ-deposits against proteolysis, thereby 
promoting plaque formation. The aim was to investigate if  SAP levels in cerebrospinal 
fluid (CSF) and serum can be used to discriminate controls, AD and mild cognitive 
impairment (MCI) patients, and to identify incipient AD among MCI patients. 
Materials and Methods: SAP levels in CSF and serum were determined in 30 controls, 
67 MCI and 144 AD patients. At follow up, 39 MCI patients had progressed to 
dementia, while 25 had remained stable (mean follow-up time: 2.6±1.0 and 2.1±0.8 
year). 
Results: Cross-sectionally no differences were found in SAP levels in CSF and serum 
between the groups. MCI patients that had progressed to dementia at follow-up had 
lower CSF SAP levels (13 μg/L (range 3.3-199.3 μg/L)) than MCI non-progressors 
(20.2 μg/L (range 7.0 - 127.7 μg/L; p<0.05). A low CSF SAP level was associated with 
a twofold increased risk of progression to AD (Hazard ratio = 2.2; 95% confidence 
interval = 0.9 - 5.4).  
Conclusion: Our data suggest that measurement of CSF SAP levels can aid in the 
identification of incipient AD among MCI patients. 
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Introduction 
Mild cognitive impairment (MCI) is characterized by an isolated memory deficit and a 
largely intact general cognitive functioning.1 Patients with MCI are at a high risk to 
develop dementia of which Alzheimer’s disease (AD) is the most common form.2,3 Early 
identification of MCI patients that progress to dementia is important in view of future 
therapeutic options. However, diagnosing incipient or prodromal AD in MCI patients 
remains a difficult issue, however and thus there is need for biomarkers that 
discriminate stable MCI cases from MCI patients who will progress to AD.  
Neuropathologically AD is characterised by neurofibrillary tangles and beta-amyloid 
(Aβ) plaques.4 A number of inflammation related factors, including serum amyloid P 
component (SAP), accumulate in Aβ plaques.5-9 Human SAP is a glycoprotein that 
exists as a pentameric ring-like structure of noncovalently bound subunits in serum.10 
SAP binds a variety of ligands, including Aβ, in a Ca2+-dependent manner.11,12 SAP 
binding to its ligands can, in turn, lead to binding of complement factor C1q and initiate 
activation of the classical pathway of the complement system. SAP binding to newly 
formed amyloid fibrils may protect the Aβ deposits from proteolysis, and as a 
consequence promote Aβ fibril and amyloid plaque formation in the brain.11,13-16 
Clustering of activated microglial cells in Aβ plaques was observed in SAP- and C1q-
containing Aβ plaques preceding tau-related neurodegenerative changes.17 In vitro, 
SAP and C1q inhibit the microglial uptake of Aβ.18 This inability to remove Aβ in the 
presence of SAP and C1q may explain the observed enhancement by SAP and C1q of 
the Aβ-mediated activation of microglia in vitro.17,19 In addition, SAP can also have 
direct effect on neuronal cells, as SAP was shown to induce apoptosis in neuronal cells 
in vitro as well as in vivo.20 These findings are indicative of a role for SAP in the 
initiation of the Aβ-mediated neuroinflammatory process in early stages of AD. It is 
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therefore conceivable that SAP levels can be used as a biomarker for early diagnosis 
of AD.  
Cross-sectional studies in which SAP levels in CSF and/or serum were measured in 
AD patients and non-demented elderly, showed contradictory results.21-25 Longitudinal 
studies in which the relation between CSF SAP levels and the clinical development of 
AD is investigated have not been reported yet. In this study, we investigated whether 
SAP levels in CSF and serum can serve as a biomarker to discriminate AD patients, 
MCI patients and controls. In addition, we followed our group of MCI patients over time, 
and investigated if SAP in CSF and serum can be used to identify incipient AD among 
MCI patients. 
 
Materials and methods 
Patients  
Sixty-seven patients with amnestic MCI, 144 patients with probable AD and 30 controls 
were included in this study. All patients underwent a standardized clinical investigation 
including medical history, physical and neurological examination, screening laboratory 
tests, and MRI. Clinical diagnosis was made by a team of neurologists, 
neuropsychologists, a radiologist, a clinical neurophysiologist and a psychiatrist, in a 
multidisciplinary meeting. The diagnosis of MCI was made according to the Petersen 
criteria.1 The diagnosis of AD was made using the National Institute of Neurological 
and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders 
Association (NINCDS-ADRDA) criteria.2 Only sporadic AD and MCI cases were 
included in this study. The control group consisted of 14 patients who presented at our 
memory clinic with subjective complaints but who had normal clinical investigations and 
did not have significant cognitive deficits (i.e. MCI criteria were not fulfilled). 
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Additionally, we included 16 volunteers without cognitive complaints, who were willing 
to undergo the same diagnostic procedure as patients attending our memory clinic. The 
Mini Mental State Examination (MMSE) was used to evaluate the degree of cognitive 
impairment.26 The local ethical review board approved the study protocol and all 
subjects gave written informed consent. Sixty-four of the 67 MCI cases were re-
examined to obtain clinical follow-up information. Two patients refused follow-up and 
one patient died before the follow-up investigation had taken place. Thirty-nine MCI 
patients (average follow-up time: 2.6±1.0 year) progressed to dementia (progressors) 
(35 AD, one dementia with Lewy bodies,27 two vascular dementia,28 one frontotemporal 
lobe dementia29 and 25 MCI patients (average follow-up time: 2.1 ± 0.8 year) remained 
clinically stable (non-progressors)).  
 
CSF analysis 
CSF samples were obtained by lumbar puncture between the L3 and L4 or L4 and L5 
intervertebral space, and 12 mL was collected in polypropylene tubes. A blood sample 
was obtained at the same time. Part of the CSF was used for routine analysis, 
including total cell and erythrocyte count, as well as total protein determination. The 
remaining CSF as well as serum samples were then centrifuged at 3,000 rpm for 10 
min at 4°C. The CSF samples were aliquoted into polypropylene tubes and 
immediately stored at -80°C until analysis. All CSF and serum analyses were 
performed at the Department of Clinical Chemistry (VUMC). CSF amyloid 1-42 (Aβ42)  
and tau were measured using commercially available sandwich ELISAs [Innogenetics, 
Ghent, Belgium].30 SAP levels in CSF and serum were determined with an in-house 
developed sandwich ELISA, using commercially available antisera (DAKO A/S, 
Denmark). Polyclonal rabbit anti-human SAP (DAKO A/S, Denmark) was coated onto 
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96-well ELISA plates (Costar high binding, USA) in 50mM carbonate buffer (pH 9.6) at 
room temperature for 18 hours. After two washes with phosphate buffered saline 
(PBS), the residual binding sites were blocked with 2%, v/v, low fat milk in PBS (150 
μL/well) for one hour at room temperature. This was followed by three times washing 
with PBT (PBS containing 0.05% Tween 20). Serum-samples (1:40,000) and CSF-
samples (1:50) were diluted with assay-buffer (PBS containing 0.1% Tween, 0.2% 
gelatin and 10mM EDTA; pH 7.4), added to wells in duplicate and incubated for 1 h. 
Bound SAP was detected after subsequent incubation with biotinylated anti-human 
SAP (DAKO A/S, Denmark) in assay buffer for 1 h and with peroxidase-labelled 
streptavidin (Amersham Biosciences, UK) for 30 min. All incubations were on a shaking 
platform (500 rpm) at room temperature. Washing in between incubation steps was 
with PBT. Finally, 3,3’,5,5’-tetramethylbenzidine (Sigma, Germany) at a concentration 
of 100µg/mL in 0.11M sodium acetate (pH 5.5) containing 0.003% H2O2 (100µL final 
volume) was used as a substrate. The substrate reaction was stopped by adding 2M 
H2SO4. Absorption at 450 nm was then determined in a Rainbow microtiter plate reader 
(SLT, Austria) and corrected for background (OD540).  
To make a standard curve we used commercially available SAP (Calbiochem cat nr. 
565190), purified from human serum. The standard curve was plotted using different 
dilutions of SAP. The detection limit for SAP was 0.1µg/L. The intra-assay coefficient of 
variance was 3.2% (N=14). The interassay coefficient of variance for three aliquoted 
pools (stored at -80°C and run each time as internal control) was 13.1% (N= 35; period 
from 2005 to 2008). 
 
Statistical analysis 
Data were analyzed with the SPSS software package (version 12.1 for Windows 
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SPSS, Chicago III., USA). Differences between groups were tested using the Fisher 
exact test, Chi-squared test, analysis of variance (ANOVA), independent t-test, Kruskal 
Wallis test and the Mann-Whitney U test. Spearman rank correlation coefficients (rs) 
between MMSE, age, Aβ1-42, tau, ApoE4 and SAP levels in CSF and serum were 
determined. Within the MCI patient group, a Cox proportional hazard model, which 
accounts for variability in length of follow-up, was used to assess the predictive value of 
CSF SAP levels within the MCI patient group. For this analysis, values of CSF SAP 
were dichotomised based on the median. Sex, age and MMSE were entered as co-
variates. The main outcome was progression to dementia, the second outcome, when 
four MCI cases that developed a different type of dementia were excluded, was 
progression to AD. The Hazard ratio (HR) is presented with 95% confidence interval 
(CI). Time to event curves were constructed with the Kaplan-Meier method. Statistical 
significance was set at p < 0.05. 
 
Results  
The clinical characteristics and the biomarker levels by diagnostic groups are shown in 
table 1. The AD, MCI and control group did not differ in sex. Patients with MCI were on 
average older than AD patients and controls (p < 0.05). ApoE4 genotype, CSF Aβ1-42 
and tau levels were significant different among the three different groups (p < 0.01). 
SAP levels in CSF and serum did not differ among diagnostic groups.  
Table 2 shows the clinical characteristics and the biomarker levels within the MCI 
group. MCI progressors had lower baseline MMSE scores than MCI non-progressors 
(p = 0.04), but there was no difference in ApoE4 genotype, age and sex. MCI 
progressors had lower baseline levels of CSF Aβ1-42 and higher CSF tau levels than 
MCI non-progressors (p<0.01). MCI patients who progressed to dementia had lower 
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CSF SAP levels, than MCI non-progressors (13 μg/L, range 3 – 199 20μg/L; 20μg/L, 
range 7 – 128 20μg/L, p<0.05). No differences in SAP levels in serum were seen 
between MCI progressors and non-progressors. The Kaplan-Meier curve for CSF SAP 
concentrations in MCI patients is presented in figure 1. After correction for sex, age and 
MMSE, the Cox proportional hazard model revealed that a low level of CSF SAP was 
associated with a twofold increased risk of progressing to dementia (HR=2.0, 95%CI 
0.9 - 4.6). The results remained essentially unchanged when the four MCI patients who 
converted to non-AD dementia were left out of the analysis (HR = 2.2, 95% CI 0.9 - 
5.4). 
SAP levels in serum and CSF were found to correlate across groups (rs=0.48, p<0.01). 
This was also observed within the AD, the MCI and the control group. (rs=0.48, p<0.01; 
rs=0.43, p<0.01; rs=0.56, p=0.01). No correlation was found between SAP levels in 
CSF or serum and CSF Aβ1-42 , tau, age, ApoE4 genotype or MMSE score (all p>0.10).  
 
Discussion 
The main finding of our study is twofold i.e. levels of SAP in CSF and serum are not 
discriminative across the three groups (AD patients, MCI subjects and controls), while 
within the MCI patient group low CSF SAP levels were associated with a twofold higher 
risk of progression to dementia, predominantly AD.  
When we cross-sectionally determined CSF SAP levels in AD patients, MCI patients 
and controls, no difference between the three groups was observed. Despite the 
increased synthesis of SAP in AD brains as shown by McGeer et al.,31 we were unable 
to detect an increase in CSF SAP levels in AD and MCI cases compared to controls. 
Possibly CSF SAP levels are not only dependent on the intraparenchymal synthesis, 
but also on accumulation in Aβ plaques17,19 and diffusion or transport across the BBB; a 
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subject for further study. Only three cross-sectional studies investigating CSF SAP 
levels in AD and controls have been reported (as summarized in table 3). In two 
studies  comparable CSF SAP levels were reported for AD and controls,21,23 which is in 
line with the cross-sectional part of our study (comparison between AD, MCI and 
controls). In the third report increased levels of CSF SAP were found in AD patients in 
comparison to controls.25 Differences in patient groups (size and age) or assay 
methods and antibodies used, may explain these contrasting results.  
The use of SAP levels in serum instead of CSF SAP levels as a biomarker for 
progression to AD has several clear advantages. However, SAP concentrations in CSF 
are approximately 3,000-fold lower than those in serum, mainly produced by the liver. 
This implies that brain-derived SAP very unlikely contributes to serum SAP levels. In 
this study no significant difference in SAP levels in serum was found between the three 
groups. SAP levels in serum have also been measured in two other cross-sectional 
studies, one showing lower SAP levels in serum of AD patients in comparison with 
controls,22 whereas the other  exhibited increased serum concentrations24 (table 3). 
The most likely reason for these differences in findings may be the group size and 
composition. Nishiyama et al.22 used relative small groups, whereas Nybo et al.24 
compared a group of cognitively impaired centenarians with age-matched controls. In 
contrast, we included relatively young controls, MCI and mild to moderate AD cases, 
which makes it difficult to compare our study with the two mentioned studies.  
Longitudinal studies in which the relation between CSF SAP levels and the clinical 
development of AD is investigated have not been reported yet. In this study we 
followed the MCI patient group for 2-3 years. The progression rate was 61% over a 
period of 2.5 years, which is slightly higher than the rate described by Petersen,1 but 
comparable to that of other memory clinics.3 The main reason for this is that because of 
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the memory clinic setting patients suspected of having AD are referred to us, which 
results in an enrichment of cases prone to develop AD. We found significantly lower 
levels of CSF SAP in MCI patients who progressed to AD in comparison with patients 
who did not progress suggesting that SAP may have potential as a biomarker to predict 
the development of AD in patients with MCI.    
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Table 1. Cross-sectional demographic and clinical information of the three groups. 
 
  AD MCI Controls p 
N 144 67 30  
Age,  Mean (SD) 66 ±  9 70 ± 9 66 ± 10 0.04 
Sex, F (%) 78 (54%) 33 (51%) 17 (43%) 0.7 
MMSE*, Mean (SD) 21 ± 5 26 ± 3 29 ± 1 <0.01 
a, b, 
c
 
ApoE4** 
Positive (%) 
 
111 (77) 
 
35 (52) 
 
4 (13) 
 
<0.01 
a, b, 
c
 
SAP CSF, μg/L  
Median (min, max) 
 
14 (2 - 
170) 
 
15 (3 - 199) 
 
15 (4 - 109) 
 
0.7 
SAP-serum, mg/L 
Median (min, max)  
 
50 (20 - 
147) 
 
51 (25 - 73) 
 
51 (27 - 87) 
 
0.6 
Aβ42, pg/ml  
Median (min, max) 
 
384 (124 – 
1,320) 
 
441 (178 – 
1,450) 
 
812 (494 - 
1142) 
 
<0.01 
a, b, 
c
 
Tau, pg/ml*** 
Median (min, max) 
 
685 (75 – 
2,615) 
 
529 (92 -
3,515) 
 
288 (129 - 
608) 
 
<0.01 
a, b, 
c
 
 
Cross-sectional demographic and clinical information of the three groups. To analyze 
the differences between the three groups we used the Chi-square test (results 
indicated in numbers with percentages in parentheses); ANOVA (results indicated as 
mean ± SD; Kruskal-Wallis in median (max, min). Post-hoc results: a = AD versus MCI 
(p<0.01); b = AD versus controls (p < 0.01); c = controls versus MCI (p < 0.01).  
*Only available for 228 subjects; ** only available for 219 subjects; ***only available for 
235 subjects.  
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Table 2. Demographic and clinical information of MCI group after follow up. 
 MCI  
Non-progressors 
MCI  
Progressors 
p 
N 25 39  
Age,  Mean (SD) 68 ± 11 70 ± 8 0.6 
Sex, F (%) 9 (36) 23 (61) 0.06 
MMSE, Mean (SD) 27 ± 2 25 ± 3 0.04 
ApoE4 
Positive (%) 
10 (40) 24 (62) 0.08 
SAP CSF, μg/L  
Median (min, max) 
20 (7; 128) 13 (3 ; 199) <0.05 
 
SAP-serum,  mg/L 
Median (min, max)  
53 (25 ; 73) 49 (35 ; 70) 0.226 
Aβ42, pg/ml  
Median (min, max) 
570 (221 ; 1450) 408 (178 ; 1148) <0.01 
Tau, pg/ml* 
Median (min, max) 
413 (92; 1156) 667 (165; 3515) <0.01 
  
To analyze the differences within the two groups we used Fisher exact test (results 
indicated in numbers with percentages in parentheses; independent t-test (results 
indicated in mean ± SD) and the Mann-Whitney test  (results indicated as median with 
range in parenthesis). *Only available for 63 subjects. 
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Table 3. Summary of published cross-sectional studies in which CSF and serum SAP are measured in patients. 
 AD Controls Cognitively  
impaired  
MCI Method Antibodies Results 
Kimura et al. 
23
 
Number 
CSF, ng/ml 
 
72 
3.7 (3.5)  
 
9 
4.0 (4.0)  
  fluid phase  
RIA 
capture:   Rabbit Anti-SAP antibody 
detection: Anti-Rabbit IgG (Calbiochem) 
no difference  
Mulder et al. 
21
 
Number 
CSF, ng/ml 
 
20 
60 (41)  
 
20 
50 (34) 
  ELISA capture: monoclonal anti-hum. SAP (aSAP-14)  
detection: rabbit anti-hum. SAP (PaSAP)     
no difference 
Hawkins et al.
25
 
Number 
CSF, ng/ml 
 
51 
12.8 (10.9)  
 
50 
8.5 (8.4)  
  solid phase  
RIA 
sheep anti-SAP antiserum 
125
I- labelled sheep anti-
SAP antiserum 
↑SAP in AD. 
Nybo et al.
24
 
Number 
CSF, ng/ml 
  
41 
32.8 (11.4)  
 
41 
48.3 (16.9)  
 Rocket  
Electroph. 
rabbit anti-human SAP IgG (DAKO®) ↓ SAP in 
Controls. 
Nishiyama et al. 
22
 
Number 
CSF, ng/ml 
 
16 
22.4 (7.0) 
 
16 
34.4 (6.6) 
  ELISA capture: goat anti-rabbit IgG (Seikagaku) and rabbit 
anti AP antiserum (DAKO®)  
detection: HRP-conjugated rabbit anti AP antiserum 
(DAKO®) 
↑ SAP in 
Controls. 
This study 
Number 
CSF, ng/ml 
Serum, μg/ml 
 
144 
19.0 (17.2) 
50.9 (15.5) 
 
30 
21.0 (20.1) 
53.0 (14.0) 
  
67 
25.0 (30.5) 
50.9 (11.0) 
ELISA capture: polycl. rabbit anti-hum. SAP antisera 
(DAKO®)  
detection: Biotinylated Rabbit Anti-hum. SAP 
antisera (DAKO®) 
 
no difference 
no difference 
SAP levels in CSF and serum are indicated as mean with SD in parenthesis.
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Figure 1. Kaplan-Meier curves for CSF SAP. CSF SAP levels were dichotomized using 
median split. The bold line indicates patients with high levels of SAP. The dotted line 
indicates low levels of SAP. The Cox proportional hazard model showed an HR = 2.0 
(95% CI 0.9 - 4.6). 
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Abstract 
Activated microglia can be visualized using (R)-[11C]PK11195 (1-[2-chlorophenyl]-N-
methyl-N-[1-methyl-propyl]-3-isoquinoline carboxamide) and positron emission 
tomography (PET). In previous studies various methods have been used to quantify 
(R)-[11C]PK11195 binding. The purpose of the present study was to determine which 
parametric method would be best suited for quantifying (R)-[11C]PK11195 binding at 
the voxel level. Dynamic (R)-[11C]PK11195 scans with arterial blood sampling were 
performed in 20 healthy and 9 Alzheimer’s disease subjects. Parametric images of both 
volume of distribution (Vd) and binding potential (BP) were obtained using Logan 
graphical analysis with plasma input. In addition, BP images were generated using two 
versions of the basis function implementation of the simplified reference tissue model, 
two versions of Ichise linearisations, and Logan graphical analysis with reference tissue 
input. Results of the parametric methods were compared with results of full 
compartmental analysis using non-linear regression. Simulations were performed to 
assess accuracy and precision of each method. It was concluded that Logan graphical 
analysis with arterial input function is an accurate method for generating parametric 
images of Vd. One of the basis function methods, one of the Ichise linearisations and 
Logan graphical analysis with reference tissue input provided reasonably accurate and 
precise estimates of BP. In pathological conditions with reduced flow rates or large 
variations in blood volume, the basis function method is preferred because it produces 
less bias and is more precise.  
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Introduction 
Microglial cells are the resident tissue macrophages of the central nervous system, 
which become activated at a very early stage1 in response to brain injury. Lower levels 
of activated microglia may also be present in normal aging and neurodegenerative 
disorders such as Alzheimer’s disease (AD). Activated microglia show increased 
expression of peripheral benzodiazepine receptors (PBR). 
(R)-[11C]PK11195 (1-[2-chlorophenyl]-N-methyl-N-[1-methyl-propyl]-3-isoquinoline 
carboxamide) is a positron emission tomography (PET) ligand for PBR, which can be 
used to assess activated microglia in vivo. Previously it has been used in a variety of 
disorders, such as multiple sclerosis, Rasmussen’s encephalitis, multiple system 
atrophy, amyotrophic lateral sclerosis and AD.2-6 In normal aging the thalamus showed 
an age-dependent increase in (R)-[11C]PK11195 binding.6 
In all previous studies (R)-[11C]PK11195 binding was quantified using a reference 
tissue approach. Both uptake normalized to a reference region7-9 and the simplified 
reference tissue model (SRTM)10 have been used.4-6,11-13 In some studies the 
cerebellum was used as a reference tissue, 3,7,12,14 in others a cluster analysis 
approach was adopted to define the normal reference region.2,4-6,12,13,15,16 
In a recent report methods to quantify (R)-[11C]PK11195 data using a metabolite 
corrected plasma input curve were investigated.17 A reversible two tissue compartment 
model with K1/k2 fixed to the value for whole cortex provided the optimal plasma input 
model. Subsequently, accuracy and precision of several reference tissue models were 
evaluated, comparing results with above mentioned plasma input model.18. In both 
studies time-activity curves (TAC) were fitted using standard non-linear regression 
algorithms. These algorithms, however, are not suitable for voxel-by-voxel calculations, 
as they are time consuming and suffer from noise amplification. In addition, region 
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based analyses require manual delineation of regions of interest (ROI), which is time 
consuming and may suffer from both inter- and intra observer variability and partial ROI 
effects.19 Therefore, interest has arisen to generate quantitatively accurate parametric 
images. These images may then be used for statistical parametric mapping (SPM) 
analyses to assess (additional) areas with significant changes in PK11195 binding,20 
thereby obtaining more accurate localization of increased PK11195 binding, which 
might have been missed using ROI based analysis. 
The purpose of the present study was to evaluate the performance of various 
parametric methods for determining (R)-[11C]PK11195 binding, considering both 
volume of distribution (Vd) and binding potential (BP) as parameters of interest.  
Binding potential represents the ratio of bound over free tracer in tissue in equilibrium. 
In case of (R)-[11C]PK11195, the tracer binds to the peripheral benzodiazepine 
receptors expressed on activated microglia, analogous to other receptor-binding 
ligands, although a large fraction of (R)-[11C]PK11195 binds non-specifically in tissue.  
In the present study parametric methods using both arterial plasma and reference 
tissue inputs were included, such as the Logan plot,21 two versions of Ichise’s 
multilinear regression,22,23 two versions of receptor parametric mapping (RPM),24,25 a 
basis function implementation of SRTM, and the reference Logan plot.26 Performance 
was evaluated using both simulations and clinical data. (R)-[11C]PK11195 binding (in 
the thalamus and whole cortex) was derived from parametric images directly and, for 
comparison, by non-linear regression of corresponding TAC using both SRTM and the 
optimal plasma input model mentioned above.  
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Methods 
Subjects 
Twenty healthy controls (10 young and 10 elderly subjects with mean  SD ages of 23 
 3 and 71  5 years, respectively) and 9 subjects (age 71 ± 6 years) diagnosed with 
probable AD, meeting NINCDS-ADRDA criteria (McKhann et al., 1984) were recruited 
between May 2002 and October 2004. Informed consent was obtained from all 
subjects. The study protocol was approved by the medical ethics committee of the VU 
University Medical Centre.  
 
Scanning procedure 
All subjects underwent a structural T1 weighted magnetic resonance imaging (MRI) 
scan using a Siemens 1.0T IMPACT scanner (Siemens Medical Solutions, Erlangen, 
Germany). PET scans were performed using an ECAT EXACT HR+ scanner 
(Siemens/CTI, Knoxville, TN, USA).27 All patients received an indwelling radial artery 
cannula for arterial sampling. After a 10 min 2D transmission scan, used to correct the 
subsequent emission scans for attenuation, a 10 min 3D dynamic [15O]H2O emission 
scan was acquired (note that results of this scan will not be presented here, as the 
focus is on parametric methods for (R)-[11C]PK11195). Next, after an interval of about 5 
min, an (R)-[11C]PK11195 PET scan was performed consisting of 22 frames with 
progressive increase in frame duration (1 x 30, 1 x 15, 1 x 5, 1 x 10, 2 x 15, 2 x 30, 3 x 
60, 4 x 150, 5 x 300 and 2 x 600 seconds; total acquisition time 60.5 minutes). Head 
movement during scanning was avoided as much as possible using a head holder. The 
first frame was used for background correction of (possible) residual [15O]H2O.  
Background correction was performed by subtracting the measured activity in the 
background frame from the subsequent frames of the study taking the decay of 15O into 
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account. At the start of the second frame, a bolus of 325 ± 84 MBq with a specific 
activity of 99 ± 38 GBq/μmol was injected using an injector (MedRad Inc, Indianola, 
U.S.A). Arterial blood was monitored continuously using an on-line detection system28 
with a withdrawal rate of 5 mL/min during the first 10 minutes and 2.5 mL/min 
thereafter. In addition, at set times (2.5, 5, 10, 20, 30, 40 and 60 minutes post-
injection), discrete manual samples were taken. These were used for calibrating the 
(on-line) blood sampler, for measuring plasma/whole blood ratios, and for determining 
metabolite fractions,29 enabling the generation of a metabolite corrected plasma input 
curve.  
 
Data analysis 
Image analysis 
Data were reconstructed using a FORE+2D filtered back projection algorithm30 with a 
Hanning filter at a cut-off of 0.3 times the Nyquist frequency, resulting in an image 
resolution of ~8.5 mm  FWHM. This resolution was chosen because in clinical studies 
parametric images will primarily be used for SPM analyses. Usually SPM analysis is 
performed with an image resolution of 8 to 12 mm FWHM and, therefore, the present 
evaluation was performed at a somewhat lower resolution than presented previously.18  
Note that this lower resolution resulted in (low) image noise levels (<15%). A zoom 
factor of 2 and an image matrix size of 256x256 were used during reconstruction, 
yielding voxel sizes of 1.2 x 1.2 x 2.4 mm3. All corrections required for quantification, 
i.e. normalisation, and attenuation, decay, scatter and random corrections, were 
applied.  
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For each subject PET and MRI scans were co-registered using a summed (R)-
[11C]PK11195 image (frames 3-12, i.e. 45s – 8 minutes) together with the software 
package MIRIT.31,32  
Using anatomical criteria, thalamus, whole cortex and cerebellum ROI were drawn on 
the co-registered MRI scan using the three-dimensional software program DISPLAY, 
developed at MNI (http://www.bic.mni.mcgill.ca/software/Display).  The cerebellum 
region was used as reference tissue. The thalamus region was chosen as it showed 
increased binding with increasing age.33 Moreover, our clinical data showed that 
variation in binding with age in healthy control subjects was larger than the range of 
binding seen in other regions (so it covered a clinically relevant range) and it was equal 
to or larger than the variation of binding seen in patients suffering from AD. Therefore, 
by using the thalamus region in young, old and AD subjects it was possible to validate 
the methods for clinical TACs with both low and high binding. Whole cortex was chosen 
to include a region with low binding, but with high count statistics. 
 
Parametric methods 
Parametric images of Vd were generated by means of the Logan plot with plasma input 
function.21 These Vd images were also processed to generate distribution volume ratio 
(DVR) images using the average Vd of the cerebellum as reference, i.e. DVR = Vd 
images divided by Vd of cerebellum. Next, BP images were derived using BP=DVR-1 
(denoted as Logan BP in the remainder of this paper). In addition, BP images were 
generated using two different linearisations: ICH122 and ICH2. With ICH2 the 
multilinear expression is rearranged to provide estimates of BP with less bias 
compared with ICH1, but at the cost of decreased precision.23 Next, BP images were 
generated using two versions of the basis function implementation of SRTM: RPM124  
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and RPM2.25 In RPM2 the washout rate constant of the reference tissue was first 
estimated using RPM1. A BP>0 threshold was used to select voxels from which the 
reference tissue washout constant was derived. The median washout value was 
calculated and subsequently its value was fixed for all voxels during a second basis 
function evaluation. The implementation was performed exactly as described by Wu 
and Carson.25 Finally, parametric BP images were created using the modified Logan 
plot with reference tissue input (reference Logan).26 In table 1 time interval and, where 
appropriate, the range of basis functions are listed for all parametric methods. These 
settings were derived empirically using e.g. the linear part of the Logan plots (these 
settings were also used for both multilinear methods) or by ‘calibrating’ the basis 
function range to provide accurate results compared with SRTM. Cerebellum was used 
as reference tissue for all reference tissue methods. ROI defined for thalamus and 
whole cortex were projected directly onto above parametric images to obtain Vd and 
BP. 
 
Non-linear regression 
ROI defined for thalamus, whole cortex and cerebellum were also projected onto the 
dynamic (R)-[11C]PK11195 scans to generate corresponding (R)-[11C]PK11195 TAC. 
Lack of patient motion, and thus proper alignment of the ROI for all frames of the PET 
study, was confirmed visually by overlaying (whole brain) contours over all frames of 
the study. Patients still showing motion were excluded beforehand. Quantification of  
(R)-[11C]PK11195 binding was obtained using the reversible two tissue plasma input 
compartment model with K1/k2 fixed to the whole cortex value
17 to obtain regional Vd (a 
two tissue compartment model was used to fit both thalamus, whole cortex and 
cerebellum TAC) and SRTM10 for determination of regional BP (of thalamus and whole 
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cortex region). Moreover, specific binding in the target region was also determined 
using DVR-1 values based on Vd values obtained with above mentioned plasma input 
model.  
 
Clinical evaluation 
Parametric imaging methods were evaluated by correlating derived Vd or BP values for 
the 29 subjects with corresponding DVR-1 and/or BPSRTM data obtained from the 
relevant non-linear regression method.  
 
Simulation studies 
Simulations were performed to assess accuracy and precision of each method as 
function of noise. For the Logan plot a typical metabolite corrected plasma input 
function18 was used to generate a noiseless normal tissue time activity curve. To this 
end, typical (R)-[11C]PK11195 rate constants (K1 = 0.055 min
-1, k2 = 0.15 min
-1, k3 = 
0.08 min-1 and BP = 2.0) were used, together with a blood volume fraction (Vb) of 0.05 
or 0.025 (i.e. target region 2 and 6 in Table 2). Noise was added to the noiseless TAC 
at set levels of 0 to 30% in steps of 2%. Distribution of variance over the frames was 
derived using the scanner’s trues rate and frame durations, and including 11C decay.34 
Noise was defined as the average noise level (%) in the frames from 5 to 60 min. 
These noise levels covered the range seen in clinical data. For 8.5 mm FWHM 
resolution data, as used in the present study, image noise levels are generally lower 
than 15%. At each noise level 10000 realizations were generated. All noisy TAC at 
each noise level were analysed using Logan plots. Accuracy was assessed by 
comparing average Logan Vd with simulated ‘true’ Vd (Table 2) and precision was 
defined as the standard deviation (SD) of the observed Logan Vd values. 
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 For reference tissue parametric methods (ICH1&2, RPM1&2 and reference 
Logan), target tissue TAC with various levels of increased specific binding were 
generated using the same input function and the two tissue compartment model 
described above. The two-tissue compartment model was used for reference and 
target region as only this model provides good fits for both reference and target tissue 
TACs. Table 2 summarizes the various parameter settings used to generate the target 
tissue TAC. To investigate reduced flow conditions, simulations were also performed 
using ~25 and 50% reductions in flow (target tissues 4 & 5). Moreover, effects of 
differences in blood volume were studied using target tissues 6-8 and reference tissue 
1-3. Similar to the Logan plot simulations, noise was added to noiseless TAC and 
10000 realizations were generated for each noise level. Each noisy TAC was analysed 
using all reference tissue parametric methods included in this study. Settings of the 
parametric methods as well as their specific implementations (e.g. determination of 
washout rate constant for RPM2) were equal to those used for clinical evaluations 
(Table 1). Average BP values and corresponding standard deviations were calculated 
for 10000 simulations. These data were compared with both true DVR-1 values (8th 
column of Table 2) and BP values obtained for noiseless TAC using SRTM (BPSRTM, 9th 
column of Table 2). Both these comparisons were performed, as it provides a means to 
discriminate between errors directly associated with the specific parametric 
implementation (e.g. linearisation) and those related more generally to the use of a 
reference tissue method (e.g. due to effect of intravascular activity).35  
 
Results  
Parametric images 
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Examples of parametric images of (R)-[11C]PK11195 binding using (A) Vd derived from 
Logan with plasma input, and BP derived from (B) Logan Vd images, (C) ICH1, (D) 
ICH2, (E) RPM1, (F) RPM2 and  (G) Reference Logan methods are shown in figure 1. 
The display scale includes negative values because for some regions (white matter) a 
negative BP was observed, which is explained by different kinetics of (R)-[11C]PK11195 
in those region as compared with the reference tissue region. In addition, R1 images 
obtained with (H) RPM1 and (I) RPM2 are shown in figure 1. 
 
Clinical evaluation 
Figure 2A shows a comparison of Vd from parametric Logan plot images (plasma input) 
with that from non-linear fitting of the corresponding TAC. Data are pooled over all 
subjects and regions, as no difference in performance of the parametric methods was 
observed amongst the subject groups tested. This may be deduced from Figures 2, 
showing that all data points are closely located near the regression line. This indicates 
a similar performance of the parametric method independent of subject group (healthy 
or AD), also in case of reference tissue input (Figure 2B). Clinical interpretation of 
results obtained for healthy versus AD subjects is, however, beyond the scope of this 
paper and will be presented elsewhere. 
Regression of logan plot data provided a Pearson’s correlation coefficient of 0.88, and 
slope and intercept were 0.93 and 0.04, respectively. In figure 2B specific BP obtained 
using RPM1 is compared with BP obtained from non-linear fitting using SRTM, whilst 
Figure 2C shows the comparison with DVR-1 based on Vd from plasma input 
modelling. Finally, in figure 2D, BP using RPM1 is plotted against DVR-1 calculated 
from Logan plot Vd values. Difference between Figure 2C and 2D is the way Vd, used 
for DVR, is obtained. Data were very similar for all other parametric reference tissue 
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methods (ICH1, ICH2, RPM2, and reference Logan). Table 3 summarizes parameters 
obtained from linear regression of the various parametric methods with the 
corresponding non-linear methods and in Table 4 these parameters are listed for linear 
regression against plasma input derived DVR-1. From the regression coefficients 
presented in Tables 3 and 4 it can be deduced that all reference tissue input based 
parametric methods have similar performance or accuracy, although RPM2 performed 
slightly worse than other reference tissue parametric methods. Table 4 and Figure 2C 
also demonstrate that, on average, BP using reference tissue input parametric 
methods (and SRTM) underestimate BP compared with plasma input derived DVR-1. 
This negative bias is different for thalamus and whole cortex regions (Figure 2C).  
 
Simulations 
In figure 3A results of simulations for the (plasma input) Logan plot are given. It can be 
seen that for noise levels up to ~15% bias in Vd
 remained relatively small (i.e. < 5%). At 
low noise levels, there was a small positive bias due to the intravascular signal, as 
demonstrated in Figure 3B, where the same plot is given but now for a target tissue 
with smaller blood volume fraction (0.025). Overall a decrease of average Vd value is 
seen with increasing noise level. In general, precisions decreased (almost linearly) to 
~20% with increasing noise level up to 30%.  
Figure 4 shows BP and its precision for the various parametric reference tissue 
methods and three levels of specific binding (DVR-1): 0.05 (top), 0.2 (middle) and 0.4 
(bottom). All parametric methods show significant underestimation relative to plasma 
input DVR-1 (black horizontal line), with a smaller discrepancy compared with BPSRTM 
(grey horizontal line). RPM1 and RPM2 more closely agreed with BPSRTM than ICH1, 
ICH2 and Reference Logan, and differences between RPM1 and RPM2 were small. 
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Moreover, at low noise levels (<5%) RPM1 only slightly underestimated BPSRTM. The 
larger discrepancy with plasma input derived DVR-1 is likely due to intravascular 
activity and might be typical for reference tissue input models. Note that BPSRTM itself 
was also around 10 to 15% lower than DVR-1 (Table 2). Precisions of the various 
parametric methods were approximately similar (right column of Figure 4). 
In Figure 5 results of similar simulations are presented, but with blood flow reduced by 
approximately 25% (top) and 50% (bottom). At these reduced flow rates, an increasing 
negative bias was found for all methods. Again, RPM1 and RPM2 results were in 
closer agreement with BPSRTM and DVR-1 values than other parametric methods. In 
case of a large (50%) flow reduction, however, all methods failed to provide an 
accurate estimate of BP.  
Finally, in Figure 6 effects of varying blood volume fraction on estimated BP are 
illustrated. In case of an increased blood volume in the target tissue (top), all reference 
tissue methods provided a larger underestimation of BP, whilst a lower blood volume 
fraction (middle) resulted in more accurate results with respect to both DVR-1 and 
BPSRTM.  More accurate results were also observed in case of a ‘matched’ lower 
(bottom) or higher (data not shown) blood volume fraction in both reference and target 
tissue region.  
 
Discussion 
In this study the performance of different parametric methods to quantify microglial 
activation in healthy and AD subjects using (R)-[11C]PK11195 and PET was evaluated 
by comparing the results of these methods with those of full compartmental analysis 
using non-linear regression (NLR), which is considered to be the gold standard for ROI 
data.  Use of accurate and precise parametric data is of interest for use within 
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statistical parametric mapping to better localize changes in PK11195 binding or to 
study PK11195 binding heterogeneity (at a voxel level). 
 
Logan graphical analysis with plasma input 
The Logan plot is a simple linear method, which allows for the estimation of the volume 
of distribution of any reversible ligand, irrespective of the number of compartments.21 
Using computer simulations, however, it has been shown that this graphical analysis 
may suffer from the presence of blood born activity and from noise induced bias.36 The 
present simulations indicate that, for (R)-[11C]PK11195, this bias is relatively small, i.e. 
lower than 5% for noise levels up to 15% (Figure 3). These latter observations are 
consistent with the excellent results obtained for clinical data, showing good correlation 
between Logan and NLR results (Figure 2A). Data observed for elderly and AD 
subjects did not differ from those obtained using younger subjects. No difference in 
noise induced bias between subject groups was observed as scan statistics are 
approximately equal for all subject groups. The latter might be explained by the fact 
that the total (specific + non-specific) binding across the entire brain is not significantly 
different between subject groups. Although noise induced bias seems small at clinically 
relevant noise levels for the present (R)-[11C]PK11195 studies, larger biases were 
observed at higher noise levels (simulation studies), consistent with the observations of 
Slifstein and Laruelle.36 The excellent correlations (0.88) for clinical data also suggest 
that, in practice, the presence of a small blood volume fraction (<0.05) may be 
neglected during Logan plot analysis. In addition, simulations indicated that the 
precision of Logan graphical analysis is more sensitive to noise than some of the 
parametric reference tissue methods. Standard deviations seen with Logan plot 
analysis were approximately two fold higher than those of reference tissue input 
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parametric methods. Reduced precision of the Logan graphical analysis also explains 
the slightly lower correlation coefficient than those found for ICH1, RPM1 and 
Reference Logan compared with BPSRTM (Table 3). Overall, it can be concluded that 
Logan graphical analysis with plasma input provides a fast and reasonably accurate 
method to obtain Vd for (R)-[
11C]PK11195 and, therefore, can be used in disorders in 
which a reference tissue cannot be defined.  
 
Parametric reference tissue methods 
Logan also introduced a non-invasive model to estimate the distribution volume ratio 
(DVR) 26 based on a reference tissue input (Reference Logan). Simulated data showed 
results with some negative bias, but high precisions at normal blood flow (Figure 4). 
Again, for clinical data there was good correlation with the NLR method (Tables 3 and 
4). Although correlations of clinical data were still reasonable, for simulated data, 
substantial bias in BP was seen compared with DVR-1 data. The larger negative bias 
in specific parametric BP with respect to DVR-1 compared to that with respect to 
BPSRTM was observed both in simulations and in clinical data (Figure 2B versus Figure 
2C). Possible reasons for this difference will be discussed below. The bias in BP was 
not only observed for the reference Logan method, but for all other parametric 
reference tissue methods (Figure 2, Tables 3 and 4).  
Ichise and coworkers22 presented a multilinear regression technique which, unlike the 
Logan plot, does not require the assumption that the ratio of concentrations in target 
and reference regions becomes constant (note that this method, which is denoted as 
ICH1 in the present manuscript, corresponds to MRTM0 in the original manuscript). As 
ICH1 contains more parameters than Reference Logan, it may, at least in theory, be 
more accurate but less precise. The present simulations showed an almost constant 
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negative bias of ICH1 of around -15 to -20% compared with BPSRTM for noise levels of 
15% (figure 4A). Larger biases were observed compared to DVR-1, as will be 
discussed later.  
To reduce noise induced bias Ichise and co-workers37 modified the operational 
equation of the multilinear regression model (this method is denoted ICH2 in the 
present manuscript and corresponds to MRTM in the original manuscript). The present 
simulations indeed showed slightly decreased bias compared with ICH1 at very low 
noise levels only. Variability, however, was much higher, even for low noise levels, 
which is consistent with results for other tracers reported by Ichise et al..23 This poorer 
precision of ICH2 is also reflected in the lower image quality seen in the clinical data 
(Figure 1). Both simulations and clinical evaluations indicate that ICH2 is not an 
improvement compared with ICH1 for obtaining (R)-[11C]PK11195 BP images. 
The present data also show that reference parametric mapping24 (denoted RPM1 in the 
present manuscript) provided the most accurate fits with relatively low variance levels. 
Correlations with NLR confirmed the robustness of this method. Both accuracy and 
precision were better than those obtained with ICH1. Simulations indicated that, in the 
presence of flow deficits, RPM1 and RPM2 show less bias and higher precision than 
Reference Logan and ICH1. These results indicate that RPM1 and RPM2 might be 
preferred for studies where changes in blood flow across the brain can be expected, 
although all methods failed to provide accurate BP values in case of very large flow 
deficits (-50%). Another advantage of RPM1 (and RPM2) is that it also provides 
parametric relative flow distributions (R1 images, Figure 1H and I). Evaluation of 
accuracy and precision of the latter R1 images is beyond the scope of the present study 
which focuses on assessment of (R)-[11C]PK11195 binding.  
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To further improve precision, Wu and Carson developed an adjusted version of this 
receptor parametric mapping method.25 In this latter method (denoted RPM2 in the 
present manuscript) a global reference region clearance rate constant k2’ was used. 
The method consists of 2 steps. First RPM1 is applied providing k2’ per pixel (in 
addition to BP and R1). Because k2’ represents the clearance rate constant of the 
reference tissue, it should be the same for all image voxels. Next, the median k2’ value 
in voxels showing a BP >0 is calculated and fixed in a subsequent RPM step. 
Simulations showed that RPM2 provided comparable BP results (including precision) 
as RPM1 for DVR-1 values of 0.2 and higher. From the example images shown in 
Figure 1H and I it can be seen that use of RPM2 will mostly improve the quality 
(precision) of the R1 images, which was confirmed by simulations showing a more than 
two-fold improvement of SD for R1 (data not shown). Thus, reducing the number of fit 
parameters within RPM2 compared with RPM1 improves R1 but does not improve 
accuracy and precision of BP. Moreover, in case of low DVR-1 values (<0.2), RPM2 
showed less accurate BP values for most of the noise levels studied. In previous 
studies38 it was observed that for most regions, including the thalamus, BP values are 
generally much lower than 0.2, even for subjects suffering from mild cognitive 
impairment or AD. The negative bias of RPM2 at these low BP values is also reflected 
in the lower values for the intercept (Table 3), indicating a small underestimation for low 
BP values. The somewhat poorer performance of RPM2 for low BP values is not yet 
fully understood, but is probably caused by small mismatches between ‘true’ and 
estimated k2’ values due to the low uptake (poor statistics) of (R)-[
11C]PK11195. In 
addition, the selection of a specific range of basis functions could affect accuracy and 
precision of both RPM1 and RPM2 (Gunn et al., 1997). Although the range and number 
of basis functions was optimised in the present study, selection of a different range 
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might lead to (slightly) different results. In practice, selection of a specific range of basis 
functions is slow and inefficient and is based on a compromise between accuracy and 
precision as has recently be investigated by Cselenyi et al..39 
 
Effects of blood volume and blood flow on accuracy of reference tissue parametric 
methods. 
In the simulation studies, a fairly constant relative underestimation of BPSRTM compared 
with plasma input derived DVR-1 was observed for all parametric reference tissue input 
methods studied. This discrepancy between ‘true’ DVR-1 and observed BP values is 
likely caused by the effects of a blood volume fraction within the TAC.  In the 8th and 
9th column of Table 2 plasma input DVR-1 and BPSRTM, calculated using noiseless 
TAC, are given. When blood volume fractions are approximately equal for both 
reference and target tissue a small underestimation of about 10% in BPSRTM compared 
with DVR-1 is seen. Reduction of flow and large differences in blood volume between 
reference and target tissues increase the difference between DVR-1 and BPSRTM. 
These differences indicate the inability of SRTM to obtain accurate (specific) BP 
estimates under these specific conditions. Note also that a larger blood volume fraction 
in the target region compared with the reference region increases R1 as can be 
deduced from Table 2, target region 7. This also explains the clearly visible sagittal 
sinus in the R1-images shown in Figure 1H and 1I. Gunn et al.24 already showed that 
presence of blood volume (i.e. intravascular activity) can affect accuracy and precision 
of SRTM. At lower flows the relative contribution of activity from blood to the total TAC 
in the early frame (<2min) increases and this explains the increased negative bias of 
SRTM (due to overestimation of R1). It can be expected that parametric methods using 
a reference tissue TAC as input function will show a similar dependency on flow and 
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blood volume fraction as SRTM. In fact, this can be observed in Figure 2C and table 4 
showing a trend for underestimation of BP for all parametric methods compared with 
plasma input derived DVR-1. The simulations also confirmed that, in general, BP 
calculated using parametric reference tissue methods most closely agreed with BPSRTM. 
Of all methods tested RPM1 most closely corresponded with results from SRTM as 
both methods are essentially the same. 
 The above considerations suggest that BP would be most accurately estimated 
from DVR-1, with Vd values obtained using a plasma input two-tissue compartment 
model, including for a parameter for blood volume fraction. In case of (R)-
[11C]PK11195, however, DVR is the ratio of two (relatively large) Vd  values having a 
very small difference, as generally BP is very low (<0.2 for the present clinical data 
including AD subjects). Consequently, BP estimates using DVR-1 will be very noisy. 
The poor correlations between parametric methods and DVR-1 in Figures 2C and 2D 
are not only due to the presence of a (variable) blood volume fraction, but also reflect 
the uncertainty in DVR-1 estimates. Estimated uncertainty of Vd for the clinical data 
was of the order of 3 to 5% and, consequently, for Vd’s around 0.7 and specific BP of 
0.1, DVR-1 will have an uncertainty of approximately 20 to 80% (or 0.02 to 0.05 = 1 
SD).  
 In addition to the above given discussion concerning the effects of blood volume 
on the accuracy of BPSRTM it should be kept in mind that both plasma input derived 
DVR-1 values and BPSRTM suffer from bias in presence of non-specific binding. 
Assuming that the reference Vd equals K1/k2*(1+k5/k6), where k5/k6 reflects non-specific 
binding potential and the target region Vd equals K1/k2*(1+k3/k4+k5/k6), where k3/k4 
represent specific BP, it can easily be seen that DVR-1 equals (k3/k4)/(1+ k5/k6). 
Consequently, DVR-1 does not provide specific BP, but a ‘specific’ BP measure which 
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value is scaled by 1+non-specific BP. Therefore, in this paper (reference tissue) 
parametric methods were also directly compared to their equivalent (non-parametric) 
method (i.e. BPSRTM). The question whether to use a certain reference tissue model has 
been addressed previously.18 Comparison of various different reference tissue models 
confirmed that SRTM provided (specific) BP values that correlated reasonably well with 
plasma input values and SRTM was recommended for the analysis of clinical PK11195 
studies.  
It can be concluded from the present study that RPM1 is the most suitable parametric 
reference tissue input method, providing BP values that most closely correspond to 
those obtained with SRTM. Clinical data indicated that ICH1 and Reference Logan 
might be good (and faster) alternatives in the absence of flow deficits. 
 
Limitations 
The methods investigated in this study represent commonly used parametric methods 
in neuroreceptor imaging. Another (third) modification of the multilinear regression 
technique, described by Ichise et al.,23 was not investigated, as this method is based 
on assuming a global reference region clearance constant k2’ for all pixels, thereby 
reducing the number of fit parameters, similar to the approach adopted in RPM2. This 
method was omitted because of the somewhat poorer performance of RPM2 for 
clinically relevant DVR-1 values (<0.2), indicating that fixing k2’ does not necessarily 
provide an advantage for obtaining BP in case of (R)-[11C]PK11195 studies.  
Other parametric methods based on using a spectrum of basis functions have been 
described. For example, application of spectral analysis (SA) in neuroreceptor PET 
studies was first described by Cunningham and Jones.40 SA can be used to obtain 
(parametric) Vd images. It has the advantage over Logan graphical analysis that it 
  80 
allows for the inclusion of high frequency basis functions, enabling the incorporation of 
a blood volume component. Therefore, in theory, SA could provide more accurate 
results than those obtained with Logan plots. Initial attempts to use SA, however, 
resulted in exceedingly long computation times. Considering these long computation 
times and the fact that Logan graphical analysis already performed very well for (R)-
[11C]PK11195, use of SA was not further attempted. Nevertheless, it should be 
mentioned that SA may outperform Logan graphical analysis for other tracers. 
 Gunn et al.41 described a method called Basis Pursuit, which is an algorithm 
related to SA, in that it uses a spectrum of basis functions. The advantage of Basis 
Pursuit over SA is that a reference tissue input function can be used. The use of a 
reference tissue input within Basis Pursuit is facilitated by including a penalty term in 
the cost function, allowing for regularisation of fits during the optimisation process. 
Unfortunately, the method is also relatively slow and considerable computation time 
and large memory stacks are needed to generate parametric images. Again, Basis 
Pursuit might be the method of choice when linear methods such as ICH1, ICH2 and  
Reference Logan do not perform satisfactorily. 
 
Conclusion  
 Logan graphical analysis is a robust and fast method to obtain parametric Vd 
images for (R)-[11C]PK11195 PET studies. Amongst the parametric reference tissue 
methods, ICH1, RPM1 and Reference Logan provide accurate and precise estimates 
of BP at normal flow rates compared with SRTM results. Simulations suggest that 
RPM1 is the best candidate for conditions with reduced flow rates, as Reference Logan 
and ICH1 show more bias than RPM1 in the presence of flow deficits.  
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Table 1. Settings used for the various parametric methods. 
Parametric method Time interval 
(min) 
Basis function range 
(min-1) 
Number of basis functions 
Logan 
30-60 - - 
ICH1 30-60 - - 
ICH2 30-60 - - 
RPM1 0-60 0.04-1.0 30 
RPM2 0-60 0.04-1.0 30 
Reference Logan 20-60 - - 
Time interval = interval used for analysis; Basis function range = range of exponentials of 
basis functions. 
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Table 2. Kinetic parameters used to generate reference and target tissue time activity curves (TAC) 
 
TAC Vb K1 (min-1) k2 (min-1) k3 (min-1) BP Vd DVR-1* BP
SRTM * R1SRTM 
Reference tissue 1 
0.05 0.055 0.15 0.06 1.5 0.9166 ---------- ---------  
Reference tissue 2 
0.025 0.055 0.15 0.06 1.5 0.9166 ---------- ---------  
Reference tissue 3 
0.075 0.055 0.15 0.06 1.5 0.9166 ---------- ---------  
Target tissue 1 
0.05 0.055 0.15 0.065 1.625 0.9625 0.05 0.047 1.0 
Target tissue 2 
0.05 0.055 0.15 0.08 2.0 1.10 0.20 0.183 1.0 
Target tissue 3 
0.05 0.055 0.15 0.10 2.5 1.28 0.40 0.35 1.0 
Target tissue 4 
0.05 0.04 0.11 0.08 2.0 0.92 0.20 0.146 0.81 
Target tissue 5 
0.05 0.0275 0.075 0.08 2.0 0.92 0.20 0.12 0.64 
Target tissue 6 
0.025 0.055 0.15 0.08 2.0 0.92 0.20 0.11 0.88 
Target tissue 7 
0.075 0.055 0.15 0.08 2.0 0.92 0.20 0.2 1.08  
Target tissue 8 
0.025 0.055 0.15 0.08 2.0 1.10 0.20 0.186 1.0 
DVR-1 represents BP obtained using DVR=ratio of target over cerebellum Vd, BP
SRTM is the BP calculated using SRTM with noiseless 
TAC. Difference between both BP measures is caused by presence of blood volume fraction in TAC which is not taken into account 
with SRTM. 
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Table 3. Results of linear regression analyses of parametric (R)-[11C]PK11195 Vd and BP with 
corresponding non-linear ROI methods. Vd obtained using two-tissue compartment model with 
plasma input and K1/k2 fixed to the whole cortex value (2T-4k) and BP obtained using BP
SRTM. 
  
  2T-4k  SRTM 
Parametric Method Slope Intercept R
2 Slope Intercept R2 
Vd Logan 0.93 0.04 0.88    
ICH1 
   0.944 -0.006 0.976 
ICH2 
   0.928 -0.004 0.911 
RPM1 
   0.948 -0.002 0.977 
RPM2 
   0.865 -0.023 0.842 
Reference Logan 
  
      0.898 -0.008 0.973 
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Table 4. Results of linear regression analyses of parametric (R)-[11C]PK11195 BP compared 
with DVR-1 based on Vd obtained using a two-tissue compartment model with plasma input 
and K1/k2 fixed to whole cortex value. 
  
  DVR-1 
Parametric Method Slope Intercept R
2 
SRTM (non-parametric NLR, ROI-TAC) 
0.702 -0.0139 0.3952 
ICH1 
0.6564 -0.0182 0.3713 
ICH2 0.7052 -0.0197 0.4242 
RPM1 0.6424 -0.0134 0.3597 
RPM2 0.6459 -0.0352 0.3677 
Reference Logan 
  
0.6456 -0.0196 0.4159 
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Figure Legends 
Figure 1: Parametric images of (R)-[11C]PK11195: (A) Vd using Logan with arterial 
plasma input, BP using (B) DVR-1 calculated using Vd Logan with plasma input, (C) 
ICH1, (D) ICH2, (E) RPM1, (F) RPM2 and (G) Reference Logan, and R1 using (H) 
RPM1 and (I) RPM2. 
 
 
Figure 2. Correlation plots of Vd and BP from parametric methods (Y-axis) versus those 
from non-linear regression of corresponding TAC (X-axis):  (A) plasma input Logan Vd  
against Vd obtained using NLR and a two-tissue compartment model with blood volume 
parameter (2TC-4k,Vb); (B) parametric BP obtained using RPM1 against BP
SRTM 
(BP(SRTM)); (C) parametric BP obtained using RPM1 against DVR-1, with DVR based 
on Vd obtained from a two-tissue compartment model with blood volume parameter 
(2TC-4k,Vb);  (D) parametric BP obtained using RPM1 against DVR-1, with DVR based 
on plasma input Logan Vd  (DVR-1 (Logan). In (C) and (D) closed symbols represent 
thalamus and open symbols whole cortex data. 
 
 
Figure 3: Bias and precision of Vd obtained using Logan analysis with arterial plasma 
input as function of noise level. Simulated TAC with (A) Vb=0.05 and (B) Vb=0.025. 
 
Figures 4: BP (A, C and E) with associated SD (B, D and F) for various parametric 
reference tissue methods as function of noise level for a ‘true’ BP(=DVR-1) of 0.05 (A, 
B), 0.2 (C, D) and 0.4 (E, F). Horizontal black solid line indicates theoretically correct 
b 
d 
e f 
G      
G    
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DVR-1 value and grey solid line BPSRTM. BP results for refererence Logan (diamonds), 
ICH1 (squares), ICH2 (circles), RPM1(triangles) and RPM2(stars) are shown. 
 
Figure 5: BP (A, C) with associated SD (B, D) for various parametric reference tissue 
methods as function of noise level for a reduced flow of approximately 25% (A,B) and 
50% (C,D). Horizontal black solid line indicates theoretically correct DVR-1 value and 
grey solid line BPSRTM. BP results for refererene Logan (diamonds), ICH1 (squares), 
ICH2 (circles), RPM1(triangles) and RPM2(stars) are shown. 
 
Figure 6: BP (A, C, E) with associated SD (B, D, F) for various parametric reference 
tissue methods as function of noise level for target tissue 6 (see Table 2 for definition of 
tissues) with reduced blood volume (A,B), for target tissue 7 with increased blood 
volume (C,D), and for target tissue 6 and reference tissue 2 showing both a reduced 
blood volume (E,F). Horizontal black solid line indicates theoretically correct DVR-1 
value and grey solid line BPSRTM. BP results for refererene Logan (diamonds), ICH1 
(squares), ICH2 (circles), RPM1(triangles) and RPM2(stars) are shown. 
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Abstract 
(R)-[11C]PK11195 has been used for quantifying cerebral microglial activation in vivo. In 
previous studies, both plasma input and reference tissue methods have been used, 
usually in combination with a region of interest (ROI) approach. Definition of ROIs, 
however, can be laborious and prone to interobserver variation. In addition, results are 
only obtained for predefined areas and (unexpected) signals in undefined areas may 
be missed. On the other hand, standard pharmacokinetic models are too sensitive to 
noise to calculate (R)-[11C]PK11195 binding on a voxel-by-voxel basis. Linearised 
versions of both plasma input and reference tissue models have been described, and 
these are more suitable for parametric imaging. The purpose of this study was to 
compare the performance of these plasma input and reference tissue parametric 
methods on the outcome of statistical parametric mapping (SPM) analysis of (R)-
[11C]PK11195 binding. 
 Dynamic (R)-[11C]PK11195 PET scans with arterial blood sampling were performed in 
7 younger and 11 elderly healthy subjects. Parametric images of volume of distribution 
(Vd) and binding potential (BP) were generated using linearised versions of plasma 
input (Logan) and reference tissue (Reference Parametric Mapping) models. Images 
were compared at the group level using SPM with a two sample t-test per voxel, both 
with and without proportional scaling. 
Parametric BP images without scaling provided the most sensitive framework for 
determining differences in (R)-[11C]PK11195 binding between younger and elderly 
subjects. Vd images could only demonstrate differences in (R)-[
11C]PK11195 binding 
when analysed with proportional scaling due to inter-subject variation in K1/k2 (blood-
brain barrier transport and non specific binding). 
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Introduction 
(R)-[11C]PK11195 (1-[2-chlorophenyl]-N-methyl-N-[1-methyl-propyl]-3-isoquinoline 
carboxamide) is a highly selective ligand for the peripheral type benzodiazepine 
receptor,1 which is mainly expressed by mitochondria in cells of the mononuclear 
phagocyte lineage. In normal human brain, the peripheral type benzodiazepine 
receptor ligand PK11195 exhibits low to minimal binding, primarily associated with the 
choroid plexus, ependymal linings and glial cells. Following neuronal damage, 
however, activated microglia, show a marked increase in expression of these sites.2-5 
Several studies on microglial activation, measured using (R)-[11C]PK11195 and 
positron emission tomography (PET), have been published.4-13 These studies have 
used different quantification methods. In general, quantification of receptor binding 
requires a mathematical model that describes the relationship between delivery (input 
function) and uptake as function of time, using non-linear regression to fit the measured 
data to this model. In a previous study14  it was shown that a reversible two tissue 
compartment model with K1/k2 fixed to whole cortex was the optimal model for 
analysing (R)-[11C]PK11195 studies when a metabolite corrected arterial plasma input 
function was available, whilst the simplified reference tissue model (SRTM15) proved to 
be the best method when no metabolite corrected arterial plasma input function was 
available.16 
Classically, quantification of receptor binding is achieved by fitting time activity curves 
(TAC), derived from predefined regions of interest (ROI), to above mentioned tracer 
kinetic models. ROI can be defined manually, which is laborious and prone to 
interobserver variability, or automatically by using a ROI template.17 With any ROI 
technique, however, results are only obtained for larger predefined areas and 
(unexpected) signals in smaller areas may be missed.  This is especially important if 
  101 
the localisation of pathology is not known a priori or when it is unlikely that this location 
exactly corresponds with a predefined ROI. Moreover, ROI analysis is based on the 
assumption that all voxels in a ROI are different statistical realisations of the same 
kinetic process, i.e. it is assumed that the underlying kinetics are homogeneous within 
a ROI. Statistical parametric mapping (SPM; Wellcome Department of Cognitive 
Neurology, University College London, UK) allows statistical analysis of neuroimaging 
data on a voxel-by-voxel basis. Commonly applied smoothing of images (up to 12 
mmm FWHM) within SPM analysis, however, also assumes some correlation in the 
kinetic process between voxels. Non-linear regression of TAC, however, is too time 
consuming and too sensitive to noise to be used at a voxel level, i.e. in case of non-
linear regression noise causes convergence problems resulting in unreliable fit results 
and fails to provide good parameter estimates. As a prelude to calculations on a voxel-
by-voxel basis, accuracy and precision of several linearised parametric methods for 
analysing (R)-[11C]PK11195 binding were evaluated,18 showing that Logan graphical 
analysis19 was a good alternative when an arterial input function was present, whilst 
Reference Parametric Mapping (RPM)20 performed best as reference tissue technique. 
It should be noted that the two parametric methods mentioned above provide different 
outcome measures. The Logan plot provides the volume of distribution (Vd), whilst 
RPM results in estimates of (specific) binding potential (BP). The purpose of the 
present study was to assess which of these two parameters, if any, had the highest 
sensitivity for detecting (known) differences in (R)-[11C]PK11195 binding between 
younger and elderly healthy subjects5,21 using SPM analyses. 
 
Methods 
Subjects 
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Seven younger (< 40 years) and 11 elderly (> 60 years) healthy subjects were 
included. All subjects were physically healthy and were not allowed to have a previous 
medical history of neurological or psychiatric disorders. This was determined by 
medical history, physical and neurological examinations, and routine blood and urine 
screening. Subjects were also screened for use of drugs of abuse. In addition, all 
subjects had a normal MRI, which was evaluated by a neuroradiologist. Finally, 
subjects had to have normal scores on neuropsychological assessments.  
Subjects were not allowed to take benzodiazepines and non-steroidal anti-inflammatory 
drugs. Written informed consent was obtained from all participants. The study protocol 
was approved by the Medical Ethics Committee of the VU University Medical Centre.  
 
Data acquisition 
PET 
PET scans were acquired using an ECAT EXACT HR+ PET scanner (Siemens/CTI, 
Knoxville, TN, USA), which has been described previously.22 All subjects received an 
indwelling radial artery canula for arterial sampling. After a 10 minutes 2D  transmission 
scan, which was used to correct the subsequent emission scans for attenuation, a 3D 
dynamic [15O]H2O emission scan was acquired, (note that results of this scan are 
outside the scope of the present study and will not be presented here). Next, after an 
interval of about 5 min,  a 3D (R)-[11C]PK11195 scan was performed consisting of 22 
frames with progressive increase in frame duration (1 x 30 background, 1 x 15, 1 x 5, 1 
x 10, 2 x 15, 2 x 30, 3 x 60, 5 x 150, 5 x 300 and 2 x 600 seconds) and a total 
acquisition time of 60.5 minutes. The first frame was used for background correction of 
(possible) residual [15O]H2O.  Background correction was performed by subtracting the 
measured activity in the background frame from the subsequent frames of the study 
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taking the decay of 15O into account. At the start of the second frame, a bolus of 259 ± 
32 MBq with a specific activity of 80 ± 34 GBq/μmol for young and 313 ± 80 MBq with a 
specific activity of 104 ± 37 GBq/μmol for elderly controls, respectively, was 
administered. Total amount of ‘cold’ PK11195 administered equalled 4.4 ± 0.2 and 3.8 
± 0.2 nmol (p=0.57) for young and elderly control subjects, respectively. Arterial blood 
was withdrawn continuously using an online detection system (Veenstra, Joure, The 
Netherlands).23 In addition, at set times (2.5, 5, 10, 20, 30, 40 and 60 minutes), 
continuous withdrawal was interrupted briefly for the collection of manual samples. 
These manual samples were used to calibrate the online blood curve, and to determine 
plasma/whole blood ratios and metabolite fractions,24 resulting in a metabolite 
corrected plasma input curve. Plasma/whole blood ratios were fitted using a multi-
exponentional fit and parent fractions were fitted using a Hill function. No systematic 
differences in input function nor it’s shape between young and elderly healthy subjects 
were observed. 
 
MRI 
All subjects had an MRI scan within five months of the PET procedure. Both T1 and T2 
weighted scans were acquired using a 1T MRI scanner (IMPACT, Siemens Medical 
Solutions, Erlangen, Germany). Voxel size of these MRI images was 0.98 x 0.98 x 1.49 
mm. 
 
Data analysis 
Generation of parametric images 
(R)-[11C]PK11195 scans were reconstructed using a FORE+2D filtered back projection 
algorithm25 and a Hanning filter with a cut-off at 0.5 times the Nyquist frequency), 
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including all corrections required for quantification, such as normalisation, and decay, 
dead time, attenuation, scatter and randoms corrections. A zoom factor of 2 and an 
image matrix size of 256x256 were used during reconstruction. Additional smoothing 
with a 10 mm FWHM Gaussian filter was performed to reduce noise to acceptable 
levels and to obtain sufficient overlap of structures between subjects for SPM analysis. 
These reconstruction (and smoothing) parameter settings resulted in an image 
resolution of ~12 mm full width at half maximum and a voxel size of 1.2 x 1.2 x 2.4 
mm3.  
Dynamic PET scans were co-registered with individual MRI scans using the software 
package MIRIT.26,27 Using anatomical criteria and the three-dimensional software 
program DISPLAY (http://www.bic.mni.mcgill.ca/software/Display), a ROI was 
delineated for total cerebellum. This ROI was projected onto the co-registered dynamic 
PET scan to generate a (total) cerebellum TAC, which was used as reference tissue 
input curve.28,29  
Finally, parametric images of Vd and BP were generated for all subjects using the 
Logan plot with a metabolite corrected arterial plasma input function19 and RPM20 with 
the cerebellum TAC as reference tissue input, respectively. For Logan plot analysis 
dynamic data from 30 to 60 min post injection were used to calculate the slope in the 
Logan plot, i.e. data from this time interval corresponds with the linear part of the Logan 
plot. This setting was used for all voxels within the brain. Regional Logan plot based Vd 
values showed a very good correlation (correlation coefficient = 0.88) with those 
derived using a two-tissue compartment model with blood volume fraction correction 
and non-linear regression analysis.18 Note also that any possible bias due to noise30 
was already minimized by performing an additional 10mm FWHM Gaussian smoothing, 
as needed for SPM analysis (see above),  prior to Logan plot analysis. For RPM the 
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entire dynamic data set was used. Basis functions ranged from 0.04 to 1.0 min-1 using 
30 basis functions. Use of these settings provided regional average BP values which 
corresponded well (correlation coefficient = 0.977) with those calculated using SRTM. 
In the present study RPM was chosen as it provided best correlations amongst various 
other parametric methods, including multi-linear approaches, and RPM is an accurate 
parametric method for reference tissue input kinetic analysis of (R)-[11C]PK11195 
studies.18 Calculation times for Logan plot analysis and RPM were 1 and 4 minutes, 
respectively, on a laptop computer with a 1.6 GHz pentium processor and 1 GB RAM. 
Parametric calculations were performed using the in-house developed software 
program PPET.31 
 
SPM analysis 
Analysis of differences in (R)-[11C]PK11195 binding between younger and elderly 
subjects was performed using SPM2 (Wellcome Department of Imaging Neuroscience, 
Institute of Neurology, University College London, UK; www.fil.ion.ucl.ac.uk/spm). Vd 
and BP images were normalised to Montreal Neurological Institute (MNI) space as 
defined by the SPM PET template as follows (Montreal Neurological Institute, Montreal, 
Canada). Each subjects PET scan was warped using a summed image of the first 120 
s of the dynamic PET scan. This summed image primarily represents a flow 
distribution, similar to the SPM PET flow template. Next, the resulting normalisation 
parameters were used to warp individual  Vd and BP images. All normalisations were 
visually checked. 
Differences between young and elderly subjects were assessed using a two-sample t-
test for each voxel. SPM analyses were performed both with and without proportional 
scaling of Vd and BP images. Vd and BP images provide quantitative measures of (R)-
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[11C]PK11195 binding parameters. Use of proportional scaling was investigated as a 
means to account for differences in blood-brain barrier transport (K1/k2 ratio) and non-
specific binding which is included in Vd. T-test statistics were evaluated by setting the 
height threshold at T = 2.58 (p < 0.01). This lower threshold was chosen as the 
methodological evaluation was the main purpose of this study. P values will be 
presented at cluster and voxel level with and without correction for multiple 
comparisons using false discovery rate (FDR) approach.32 
 
Results 
In figure 1 typical Vd and BP images are shown for both a younger and an elderly 
subject.  
Parametric BP images, without proportional scaling, showed a significant increase in 
(R)-[11C]PK11195 binding in elderly compared to younger subjects in the left and right 
frontal cortex, left and right medial temporal cortex and left and right thalamus at a 
threshold of p = 0.01, uncorrected for multiple comparisons (figure 2a, table 1). In 
addition, increased (R)-[11C]PK11195 binding in the midbrain was found. Using 
proportional scaling, the same regions also showed significantly increased (R)-
[11C]PK11195 binding, but to a lesser extent.  
Vd images with proportional scaling showed increased (R)-[
11C]PK11195 binding in the 
left and right frontal cortex, left thalamus and right medial temporal lobe (figure 2b, 
threshold p = 0.01). These regions did not reach the threshold for significance when 
absolute scaling was used (table 2), not even at an uncorrected level. P values with 
and without multiple comparison corrections for BP is given in Table 1 and for Vd table 
2. 
  107 
In table 3 the cluster extents at a threshold of p = 0.01  are summarized for the different 
parametric methods. The exact cluster size could not be established for all regions due 
to merging of clusters. Cluster sizes of BP images were significantly larger than those 
of corresponding clusters derived from Vd images.  
 
Discussion 
Using SPM analyses, in the present study the performance of Logan19 and RPM20 
parametric methods was assessed for the young-versus-old paradigm. In the present 
study differences in the thalamus between young and elderly healthy subjects as well 
as in other cortical regions could  be demonstrated at a cluster level, although they 
were not statistically significant at a voxel level after correction for multiple 
comparisons. The observed differences are consistent with previous studies that 
showed an age-dependent increase of  (R)-[11C]PK11195 binding in the thalamus.5,21  
The clinical relevance of these differences will be reported elsewhere, as this is beyond 
the scope of the present study, which is concerned with the sensitivities of two different 
parametric methods.   
 
Vd versus BP images 
In a previous study18,33  it was shown that Logan graphical analysis19 (with metabolite 
corrected plasma input function) provides a fast, precise and accurate method for 
generating parametric Vd images of (R)-[
11C]PK11195. Major disadvantages of this 
method are, however, the need for both arterial cannulation and labour intensive 
measurements of plasma metabolite fractions. In addition, Vd is a measure of total 
(specific and non-specific) binding and intersubject variability in the (relatively large) 
nonspecific component may prohibit the detection of more subtle changes in specific 
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binding. Moreover, as will be discussed later, variation in Vd may reflect changes in 
transport across the blood-brain barrier more than changes in BP. 
Previously, it has been shown that the simplified reference tissue model is the best 
method for quantifying specific binding (BP) if no plasma input function is available.16 
The RPM method,20 which is based on this model, proved to be the optimal method for 
generating parametric BP images of (R)-[11C]PK11195.18 Compared to Logan with 
plasma input, this method is less invasive and provides a measure of specific binding 
rather than of total uptake. It depends, however, on the assumptions that a region 
devoid of receptors exists and that the level of non-specific binding is the same as that 
in the reference region. Another potential limitation is that BP may be biased depending 
on the amount of non-specific binding.16 Consequently, subtle changes in BP could 
potentially be obscured by a varying degree of bias resulting from intersubject 
variability in nonspecific binding.  
Finally, BP obtained by SRTM may be biased by global and regional cerebral blood 
flow (CBF) differences. Therefore, the [15O]H2O studies were analysed to determine 
CBF of total grey matter, as measure of global flow, of the thalamus, as this region was 
found to show increased binding in elderly subjects during SPM analysis, and of the 
cerebellum, which was used a reference region. Global (total grey matter) CBF 
differences were not significant (p=0.29) and equalled 0.38 ± 0.08 and 0.43 ± 0.09 
ml/min/ml for young and elderly subjects, respectively. Thalamus and cerebellum CBF 
were comparable and also did not show signifant difference in CBF between young and 
elderly subjects. As global CBF was not significantly different between subject groups it 
is assumed that observed differences in BP are not caused by (global) CBF 
differences. Moreover, CBF between reference region (cerebellum) and thalamus 
correlated well (Pearson’s correlation coefficient = 0.83, slope=1.06 and percentage 
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difference ranged from -15 to +12%). This result indicates that there are no large 
regional differences in CBF between thalamus and reference regions for all subjects 
studied. Simulations (data not shown) confirmed that BP obtained with SRTM is 
(almost) independent of global flow differences (bias ranged from -8.5 to -12.3 using 
global flow variation of 0 to 100%). However, in case of a regional flow differences of -
20% between thalamus versus reference region, BP with SRTM showed a bias of -18% 
versus -11% in absence of flow difference, consistent with previously reported results.18 
As observed regional flow differences were small (6% on average and maximum 
difference <15%) it may be assumed that the observed increased BP in elderly 
subjects found during SPM analysis was not affected by blood flow effects. 
 
Absolute versus proportional scaling  
In case of parametric (R)-[11C]PK11195 Vd images, proportional scaling might be used 
to (partially) account for inter-subject differences in K1/k2 ratio, i.e. differences in Vd of 
the ‘free’ tracer compartment in tissue, across subjects. Note that this ratio also 
includes the contribution of non-specific binding with ‘fast’ kinetics so that it is merged 
with the ‘free’ compartment. To validate this assumption, whole cortex plasma input Vd 
and BP values, obtained by non-linear regression, were plotted against whole cortex 
K1/k2 ratios per subject (Figure 3). Vd and BP values were calculated using a plasma 
input two-tissue compartment model which included a correction for blood volume 
fraction providing values for the rate constants K1, k2, k3, k4. Vd and BP were then 
calculated using Vd=K1/k2*(1+BP) and BP= k3/k4. Figure 3 shows a clear correlation 
between global K1/k2 ratio and (total) Vd, but not with plasma input BP. Average whole 
cortex plasma input BP, Vd and K1/k2 were not statistically different between young and 
elderly subjects. These results illustrate that variations in Vd across subjects are mainly 
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determined by variations in K1/k2 ratio. Use of proportional scaling may then be useful 
to account for differences in (bidirectional) transport across the blood-brain barrier and 
any fast kinetic components of non specific binding. It is assumed that these rescaled 
Vd values may be used as a measure of total binding as Vd=K1/k2*(1+BP) and thus that 
rescaled Vd is proportional to 1+BP. The latter hypothesis might also explain the trend 
for detecting similar areas with increased binding when using proportional scaling as 
those seen with BP images (used without scaling). In this specific case use of 
proportional scaling of Vd images may be justified because of the very high correlation 
(Pearson’s correlation coefficient of 0.98, see Figure 3) between global Vd and K1/k2.  In 
general, however, proportional scaling should be used with care as proportional scaling 
may result in both false negative and positive results.  
An alternative to proportional scaling may be scaling by the Vd of the reference tissue 
(cerebellum in this study) per subject. The latter approach would provide distribution 
volume ratio (DVR) images. However, DVR equals 1+BPSRTM and only provides an 
(exact) offset of 1.0 to RPM images.  Use of DVR images will therefore provide SPM 
results equal to those obtained with RPM data. 
It is likely that proportional scaling of  (R)-[11C]PK11195 BP images will lead to 
erroneous results. In normal brain (R)-[11C]PK11195 BP will be close to zero (no 
activated microglia). Proportional scaling would thus depend on the level and extent of 
specific binding, which in turn might lead to reduced sensitivity of detecting significant 
differences. Proportional scaling should therefore not be performed for parametric BP 
data.  
 
Evaluation of parametric methods and SPM scaling strategies 
SPM analysis of parametric BP images without proportional scaling provided results 
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with lower p-values and more voxels above the SPM threshold than those with 
proportional scaling. This is probably due to the low level of specific (R)-[11C]PK11195  
binding in most areas of the normal brain. The effect of proportional scaling will 
therefore be disproportionately high, effectively resulting in increased intersubject 
variability of areas with specific binding and thus in decreased significance of detected 
differences. Proportional scaling should therefore not be performed for parametric BP 
data. 
In contrast, SPM analysis of parametric Vd images improved with proportional scaling 
and proportional scaling may act as a correction for differences in blood-brain barrier 
transport across subjects and (the fast component of) non specific binding (Figure 3). 
It is concluded that use of parametric BP data without (proportional) scaling is most 
suitable for SPM based assessment of change in (R)-[11C]PK11195  binding between 
young and elderly subjects.  
 
Limitations of present study 
A limitation of this study might be the use of the cerebellum as a reference tissue, as 
the cerebellum might be inadequate as a reference region.34 In a previous study in 
healthy subjects and patients with mild cognitive impairment and Alzheimer’s disease, 
cerebellum and cluster analysis showed comparable performance as reference tissues 
in a full compartmental analysis.28 Resulting BP values were reasonably well correlated 
(r = 0.69). More importantly, that study also demonstrated that observed differences in 
thalamic binding between young and elderly control subjects were similar for both 
reference tissues. However, increase of specific binding in the cerebellum of elderly 
controls compared with young controls may still be present. Increased binding in a 
reference tissue will result in underestimation of specific binding in target regions. In 
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the present study, observed changes in BP (amplitude and extent) using RPM BP 
images may therefore have been underestimated. Fortunately, this does not affect the 
conclusion that reference tissue parametric analysis providing BP images outperforms 
parametric plasma input Logan analysis providing Vd images for SPM of (R)-
[11C]PK11195 studies in healthy controls. 
  
Conclusion 
SPM analysis of parametric BP images has the highest sensitivity for detecting 
changes in specific (R)-[11C]PK11195 binding between young and elderly subjects. As 
parametric BP images already represent quantitative measures of specific binding, use 
of proportional scaling is not necessary and, in fact, will only result in reduced 
significance of observed differences. Moreover, it may even result in false positive or 
negative results and it should not be performed. Parametric Vd images were less 
suitable for SPM analysis and required proportional scaling to account for differences in 
K1/k2 ratio across subjects.  
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Table1. P values of detected differences in [11C](R)-PK11195 binding between young 
and elderly healthy subjects for RPM BP images analysed without proportional scaling.  
  Voxel level 
Clusler level 
Region Puncorrected Pcorrected Puncorrected Pcorrected 
Left Thalamus < 0.0001 0.045 <0.0001 <0.0001 
Right Thalamus < 0.0001 0.045 <0.0001 <0.0001 
Left Frontal Lobe < 0.0001 NS <0.0001 <0.0001 
Right Frontal Lobe < 0.0001 NS <0.0001 <0.0001 
Left Medial Temporal 
lobe < 0.0001 
0.049 
0.011 NS 
Right Medial Temporal 
Lobe < 0.0001 
NS 
<0.0001 <0.0001 
Midbrain 0.001 NS NS NS 
NS = non-significant (set at p > 0.05)  
Uncorrected and corrected p values at voxel and cluster level are shown. 
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Table 2. P values of detected differences in [11C](R)-PK11195 binding between young 
and elderly healthy subjects for Logan Vd images analysed with proportional scaling.  
  Voxel level Cluster level 
Region Puncorrected Pcorrected Puncorrected Pcorrected 
Left thalamus 0.003 NS NS NS 
Right thalamus NS NS NS NS 
Left frontal lobe <0.0001 NS 0.049 NS 
Right frontal lobe 0.004 NS <0.0001 <0.0001 
Left medial temporal lobe 0.018 NS NS NS 
Right medial temporal lobe 0.005 NS NS NS 
Midbrain 0.021 NS NS NS 
NS=non-significant (set at p >0.05 in this table) 
Uncorrected and corrected p values at voxel and cluster level are shown. 
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Table 3. Cluster extent of areas with significant differences in [11C](R)-PK11195 binding 
between young and elderly healthy subjects for the various parametric methods, at a 
set threshold of p = 0.01.  
  BP Vd 
Region 
 
Absolute 
(ml) 
Proportional 
(ml) 
Absolute 
(ml) 
Proportional 
(ml) 
Left Thalamus 115* 15.5** 0    0.02 
Right Thalamus 115* 12.0*** 0    0 
Left frontal 115*          1.2 0 1.6 
Right frontal 115*          2.0 0 0.8 
Left Medial temporal lobe 115* 15.5** 0     0 
Right Medial temporal lobe 115*   12.0*** 0   0.2 
Midbrain   1.2   0.36 0     0 
 
*/**/*** = merged regions 
Note that in case of SPM analysis of BP images with absolute scaling most activated 
voxels are merged into one large cluster. 
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Figure legends 
Figure 1: Representative parametric Vd (a and c) and BP (b and d) images of  [
11C](R)-
PK11195 binding in a young (age=30) (a and b) and an elderly (age=77) (c and d) 
subject. 
 
Figure 2. Statistical parametric maps (p = 0.01, T >2.58) showing  differences in 
[11C](R)-PK11195 binding between young and old healthy control subjects using (a) BP 
images without proportional scaling and (b) Vd images with proportional scaling. 
 
Figure 3. Plasma input whole cortex BP (diamonds) and Vd (circles) as function of 
whole cortex K1/k2 ratio. Closed and open symbols correspond to data of elderly and 
young subjects, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  121 
 
Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  122 
Figure 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  123 
Figure 3 
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Chapter 4 
 
 
 
Quantification of microglial activation in 
normal aging and in Alzheimer’s disease,   
using (R)-[
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C]PK11195 and PET 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  125 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  126 
Microglial activation in healthy aging 
 
 
 
 
Alie Schuitemaker MD1,2 
Thalia F van der Doef MSc2,5 
Ronald Boellaard PhD2 
Wiesje M van der Flier PhD1,3 
Maqsood Yaqub2 
Albert D Windhorst PhD2 
Frederik Barkhof4 
Cees Jonker MD PhD1 
 Reina W Kloet Msc2 
Adriaan A Lammertsma PhD2   
Philip Scheltens MD PhD1 
Bart N M van Berckel MD PhD2 
 
 
1Department of Neurology & Alzheimer Center 
2Department of Nuclear Medicine & PET Research  
3Department of Epidemiology and Biostatistics 
4 Department of Radiology 
VU University Medical Center, Amsterdam, the Netherlands 
5Department of Psychiatry, Rudolf Magnus Institute for Neuroscience 
 
 University Medical Center Utrecht, Utrecht, the Netherlands 
 
Neurobiol. Aging. In press. 
  127 
Abstract 
Healthy brain aging is characterized by neuronal loss and decline of cognitive function. 
Neuronal loss is closely associated with microglial activation and post mortem studies 
have indeed suggested that activated microglia may be present in the aging brain. 
Microglial activation can be quantified in vivo using (R)-[11C]PK11195 and positron 
emission tomography. The purpose of this study was to measure specific binding of 
(R)-[11C]PK11195 in healthy subjects over a wide age range.  
Thirty-five healthy subjects (age range 19 – 79 years) were included. In all 
subjects 60 minutes dynamic (R)-[11C]PK11195 scans were acquired. Specific binding 
of (R)-[11C]PK11195 was calculated using receptor parametric mapping in combination 
with supervised cluster analysis to extract the reference tissue input function.  
Increased binding of (R)-[11C]PK11195 with aging was found in frontal lobe, 
anterior and posterior cingulate cortex, medial inferior temporal lobe, insula, 
hippocampus, entorhinal cortex, thalamus, parietal and occipital lobes, and cerebellum. 
This indicates that activated microglia appear in several cortical and subcortical areas 
during healthy aging, suggesting widespread neuronal loss.  
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Introduction 
Microglia cells are related to cells of the mononuclear cell phagocyte lineage and 
become activated at a very early stage in response to a pathological event. Growing 
evidence points to microglial activation as an early and ongoing event in several 
neurodegenerative disorders.1,2 From postmortem studies it is known that microglial 
activation is also present in the normal brain.3-6 For instance, it has been reported that 
activated microglia increase in the temporal lobe with healthy aging.3,5 Furthermore, 
microglial activation may be related to neuronal loss and decline of cognitive function.7 
 (R)-PK11195 (1-[2-chlorophenyl]-N-methyl-N-[1-methyl-propyl]-3-isoquinoline 
carboxamide) is a highly selective ligand for the peripheral type benzodiazepine 
receptor, also called the 18 kDa translocator protein  (TSPO),8,9 which, in the brain, is 
upregulated in activated microglia cells. When labelled with the positron emitter carbon-
11 (11C), it can be used to quantify microglial activation in vivo using positron emission 
tomography (PET). This approach has already been used in the study of several 
neurodegenerative disorders.7,10-12 
 Little is known about the role of activated microglia in healthy aging. Initial 
studies showed increased (R)-[11C]PK11195 binding in the thalamus.7,11,13 However, 
other areas in the brain have not been evaluated extensively. Therefore, the purpose of 
this study was to examine effects of aging on microglial activation in healthy brain using  
(R)-[11C]PK11195 and PET.  
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Methods 
Subjects 
Thirty-five healthy subjects were included in the study, 13 women and 22 men. Two of 
the subjects were excluded from further analyses due to movement artefacts resulting 
in unreliable fits. Subjects were recruited by advertisement in local newspapers and 
underwent standardized clinical assessment, including medical history, physical and 
neurological examinations, and laboratory tests. All subjects had normal scores on 
screening laboratory tests and a normal MRI, as evaluated by a neuroradiologist (FB). 
In addition, all subjects older than 55 years underwent a neuropsychological 
assessment and had a normal performance score on the cognitive test battery (Mini-
Mental State Examination, Rey’s Auditory Verbal Learning Test, Rey’s Complex Figure, 
Trail Making Test, Boston Naming Test and Digit Span).  
Exclusion criteria were major psychiatric illness, a history of alcohol or 
substance abuse according to DSM-IV criteria,14 cognitive complaints, previous head 
trauma with loss of consciousness of more than one hour duration, and significant 
metabolic disorder or pregnancy. Intake of benzodiazepines, antipsychotic drugs and 
non-steroidal anti-inflammatory drugs was not allowed, because of possible interaction 
with (R)-[11C]PK11195 binding.  
Written informed consent was obtained from all participants. The study protocol 
was approved by the Medical Ethics Review Committee of the VU University Medical 
Centre. 
 
MRI 
All subjects had a structural MRI scan within four months of the PET procedure. MRI 
scans were acquired using a 1.0 T scanner (Magnetom IMPACT, Siemens Medical 
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Solutions, Erlangen, Germany) and included a 3D heavily T1-weighted gradient echo 
sequence (MP-RAGE). Voxel size of the MRI images was 0.98 x 0.98 x 1.49 mm. 
These scans were used both for segmentation of grey and white matter, and for 
delineation of regions of interest (ROI).  
 
Production of (R)-[11C]PK11195  
(R)-[11C]PK11195 was produced as described previously 9 according to GMP 
guidelines (Eudralex 4) in the government licensed (no. 108897F) GMP facility of the 
department of Nuclear Medicine & PET Research. The product was obtained as a 
sterile and pyrogen free solution in phosphate buffered saline (pH 5.4-6.0) with a 
(radio)chemical purity of > 98% and a specific activity (SA) of 52-132 GBqµmol-1. 
 
PET 
PET scans were acquired using an ECAT EXACT HR+ (Siemens/CTI, Knoxville, TN, 
USA).15 First, a 10 minutes transmission scan was performed in 2D acquisition mode 
using three retractable rotating line sources. This scan was used to correct the 
subsequent emission scan for photon attenuation. Then, a 3D dynamic (R)-
[11C]PK11195 emission scan was performed consisting of 22 frames with progressive 
increase in frame duration (1 x 30 s background, 1 x 15, 1 x 5, 1 x 10, 2 x 15, 2 x 30, 3 
x 60, 4 x 150, 5 x 300 and 2 x 600 s; total acquisition time 60.5 minutes). Detailed 
scanning and sampling procedures have been published previously.16 Subject motion 
during scanning was checked visually at regular intervals (using laser beams) and 
corrected immediately, if necessary. Moreover, motion was minimised by using a head 
immobilisation device (head holder). 
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2.5. Image reconstruction  
All PET sinograms were corrected for dead time, tissue attenuation using the 
transmission scan, decay, scatter and randoms. Data were reconstructed using a 
partial volume corrected (PVC) ordered subset expectation maximisation (OSEM) 
reconstruction algorithm that incorporates the scanner’s point spread function in the 
system matrix during reconstruction. This algorithm has been described in detail and 
was validated previously.17 A zoom factor of 2 and a matrix size of 256 x 256 x 63 were 
used, resulting in a voxel size of 1.2 x 1.2 x 2.4 mm and a spatial resolution of 
approximately 2.5 mm full width at half maximum in the centre of the field of view. 
 
Regions of interest definition 
For each subject, PET and MRI scans were co-registered using the software package 
MIRIT.18,19 ROIs were defined using a probability map based on automatic brain 
delineation.20 ROIs in this template included the frontal cortex (volume weighted 
average of superior frontal, orbital frontal and medial inferior frontal cortex), anterior 
and posterior cingulate cortex, superior temporal and medial inferior temporal lobe, 
insula, hippocampus and entorhinal cortex, thalamus, parietal cortex, sensory motor 
cortex, occipital cortex and cerebellum.  
 
Tracer kinetic modeling 
Parametric images of (R)-[11C]PK11195 PET scans were generated using receptor 
parametric mapping, (RPM),21 a basis function implementation of the simplified 
reference tissue model (SRTM).22 RPM was found to be the most suitable parametric 
method for analysis of (R)-[11C]PK11195 scans.16 Supervised cluster analysis was 
used to extract the reference tissue input curve directly from the dynamic (R)-
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[11C]PK11195 data.23 The primary outcome measure was binding potential (BPND).
22,24 
Regional values of BPND were obtained by projecting the template ROIs, defined 
above, onto the parametric BPND images. 
 
Statistical analysis 
Statistical analysis of ROI data was performed using SPSS software (SPSS Institute, 
Chicago, Ill, USA), version 15.0. Values are presented as mean ± standard deviation 
(SD). Linear regression analysis was performed using BPND as dependent variable and 
age (continuous) as independent variables. Sex was entered as covariate. Regression 
coefficients (B) and standard errors (SE), as well as correlation coefficients are 
presented. The threshold for significance was set at p < 0.05.  
 
Results 
Data from a total of 33 subjects (mean age 53.4 ± 21.0; range 19 – 79 years, 11 
females) were available for analysis. Mean tracer dose at time of injection was 322 ± 
100 MBq and mean SA at time of injection 88 ±33 Gbqμmol-1. There was no 
association between injected dose and age (B(SE) = -1.134 (0.837)). Estimated 
receptor occupancy associated with these high SA tracer doses was < 1%.  
Linear regression analysis showed that increasing age was associated with 
increased (R)-[11C]PK11195 BPND throughout several cortical and subcortical brain 
regions, namely frontal cortex, anterior and posterior cingulate cortex, parietal and 
occipital cortex, thalamus and cerebellum. Age-related increases were also found in 
various temporal regions: medial inferior temporal lobe, insula, hippocampus and 
entorhinal cortex (table 1; figure 1).  
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Discussion 
The main finding of the present study is an increase in (R)-[11C]PK11195 binding with 
healthy aging in frontal lobe, cingulate anterior and posterior cortex, medial inferior 
temporal lobe, insula, hippocampus, entorhinal cortex, thalamus, parietal and occipital 
lobes, and cerebellum. This age-related increase in (R)-[11C]PK11195 specific binding 
in several cortical and subcortical structures indicates that activated microglia gradually 
appear in the aging human brain, suggesting the appearance of some degree of 
neuronal damage. 
There are very few in vivo human data on the effect of aging on (R)-
[11C]PK11195 binding in the healthy brain. Cagnin et al. were the first to report (R)-
[11C]PK11195 binding in a small group of healthy control subjects (age range 32 – 80 
years).7,11 Brainstem and thalamus were the only regions showing increased (R)-
[11C]PK11195 binding relative to the reference tissue, but an age effect was only seen 
in the thalamus and the same finding was reported by Ouchi et al. (age range 39 – 70 
years),13 whereas Debruyne et al. did not find such an age related increase (age range 
23 – 41 years).25 Since the thalamus is a nucleus with many reciprocal cortical 
connections, it has been thought that increased (R)-[11C]PK11195 binding might reflect 
neuronal injury in other brain areas.7  
Higher levels of (R)-[11C]PK11195 binding with normal aging were also found in 
the (medial) temporal lobe, which is in agreement with postmortem studies describing 
an increase in activated microglia in the hippocampus.3,5 Interestingly, markers of 
microglial activation were associated with neurofibrillary tangles,5 another marker of 
neuronal loss. In addition, an age dependent decline of cortical grey matter thickness 
with normal aging has also been described in the temporal cortex.26,27 Both activated 
microglia and cortical atrophy indicate that neuronal damage occurs in the temporal 
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lobe during healthy aging. This is consistent with the high prevalence of memory 
disorders in elderly subjects, as the temporal lobe is crucial for memory function. 
Common regional cerebral atrophy with aging has been described previously 
and includes prominent grey matter loss in frontal areas, but also atrophy in anterior 
cingulate cortex, temporal, parietal and subcortical areas as well as in insula,27,28 again 
consistent with increased binding of (R)-[11C]PK11195 in these areas. Interestingly in 
frontal cortex as well as in anterior and posterior cingulate a strong association 
between atrophy and local beta-amyloid deposition in subjects with subjective cognitive 
impairment was found.29  
The age related increase in (R)-[11C]PK11195 binding in several cortical and 
subcortical structures indicates that activated microglia appear in the aging human 
brain. The processes underlying microglial activation in normal aging are complex and 
poorly understood and their functional implications remain an enigma. However, it is 
well known that microglial activation is closely associated with neuronal damage. 
Whether microglial activation with aging is a secondary effect of age related neuronal 
damage due to other causes, or more directly involved in neuronal degeneration is not 
clear.30 If microglial activation is a causative factor for neuronal degeneration, it could 
be an important target for treatment of age related cognitive problems. 
Strengths of the present study are the relatively large sample size and the wide 
age range of subjects included, as well as the number of cortical regions evaluated. A 
limitation might be that although (R)-[11C]PK11195 is a selective ligand for the 
peripheral benzodiazepine receptor, it is not ideal, as it has a relatively low specific to 
non-specific binding ratio and a very low extraction fraction. In addition, only elderly 
subjects without subjective memory complaints were selected and a 
neuropsychological assessment was performed to rule out subjects with cognitive 
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deficits. Nevertheless, it is conceivable that, although performance on neurological 
examination and neuropsychological assessment was normal, subjects were included 
with preclinical neurodegenerative disorders, which by themselves are associated with 
microglia activation. This might explain the heterogeneity of results in medial temporal 
lobe areas, noting that microglial activation may be present years before symptoms 
emerge.31  
In previous studies it has been shown that the most accurate parametric 
method for analysing (R)-[11C]PK11195 data is RPM with cerebellum as reference 
tissue.16 In healthy control subjects, however, definition of a reference region can be 
difficult, as it requires delineation of an unknown region without microglial activation. 
Therefore, a supervised cluster analysis method was used for extracting the reference 
tissue input function.23,32 Turkheimer et al. demonstrated that this method provides a 
robust and reproducible quantitative assessment of (R)-[11C]PK11195 binding in the 
human brain.23 By applying this method, increased (R)-[11C]PK11195 BPND was found 
in the cerebellum. Consequently, in the absence of plasma input data, the use of the 
cerebellum as reference region in healthy aging studies is not appropriate.  
An increasing degree of brain atrophy might affect the assessment of (R)-
[11C]PK11195 binding with age. To limit partial volume effects, in the present study a 
PVC-OSEM reconstruction algorithm was used. This algorithm uses the scanner’s 
point spread function to enhance the spatial resolution of reconstructed scans to a level 
that closely meets the physical properties of the PET scanner. This method was 
recently validated by Mourik et al. for the HR+ scanner33 and is presently incorporated 
in some of the latest PET/CT systems to improve resolution and image quality (so-
called ’resolution recovery’). Despite this, it is likely that observed BPND values still 
underestimate both extent and magnitude of microglial activation. It might be 
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hypothesized that in relatively small regions surrounded by cerebrospinal fluid, such as 
the hippocampus and entorhinal cortex, a disproportionate underestimation of the true 
signal occurs. This might explain the discrepancy with post-mortem studies describing 
an increase in activated microglia in the hippocampus.3,5 
 In conclusion, increased (R)-[11C]PK11195 binding with healthy aging was 
found in frontal lobe, cingulate anterior and posterior cortex, medial inferior temporal 
lobe, insula, hippocampus, entorhinal cortex, thalamus, parietal and occipital lobes, 
and cerebellum suggesting the appearance of widespread neuronal damage during 
normal aging.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  137 
References 
 
 1 Neumann H, Kotter MR, Franklin RJ. Debris clearance by microglia: an essential 
link between degeneration and regeneration. Brain 2009; 132(Pt 2):288-295. 
 2 Hanisch UK, Kettenmann H. Microglia: active sensor and versatile effector cells in 
the normal and pathologic brain. Nat Neurosci 2007; 10(11):1387-1394. 
 3 DiPatre PL, Gelman BB. Microglial cell activation in aging and Alzheimer disease: 
partial linkage with neurofibrillary tangle burden in the hippocampus. J 
Neuropathol Exp Neurol 1997; 56(2):143-149. 
 4 Rogers J, Luber-Narod J, Styren SD, Civin WH. Expression of immune system-
associated antigens by cells of the human central nervous system: relationship to 
the pathology of Alzheimer's disease. Neurobiol Aging 1988; 9(4):339-349. 
 5 Sheng JG, Mrak RE, Griffin WS. Enlarged and phagocytic, but not primed, 
interleukin-1 alpha-immunoreactive microglia increase with age in normal human 
brain. Acta Neuropathol 1998; 95(3):229-234. 
 6 Streit WJ, Sparks DL. Activation of microglia in the brains of humans with heart 
disease and hypercholesterolemic rabbits. J Mol Med 1997; 75(2):130-138. 
 7 Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE, Jones T, 
Banati RB. In-vivo measurement of activated microglia in dementia. Lancet 2001; 
358(9280):461-467. 
 8 Papadopoulos V, Baraldi M, Guilarte TR, Knudsen TB, Lacapere JJ, Lindemann 
P, Norenberg MD, Nutt D, Weizman A, Zhang MR, Gavish M. Translocator 
protein (18kDa): new nomenclature for the peripheral-type benzodiazepine 
receptor based on its structure and molecular function. Trends Pharmacol Sci 
2006; 27(8):402-409. 
 9 Shah F, Hume SP, Pike VW, Ashworth S, McDermott J. Synthesis of the 
enantiomers of [N-methyl-11C]PK 11195 and comparison of their behaviours as 
radioligands for PK binding sites in rats. Nucl Med Biol 1994; 21(4):573-581. 
 10 Banati RB, Newcombe J, Gunn RN, Cagnin A, Turkheimer F, Heppner F, Price G, 
Wegner F, Giovannoni G, Miller DH, Perkin GD, Smith T, Hewson AK, Bydder G, 
Kreutzberg GW, Jones T, Cuzner ML, Myers R. The peripheral benzodiazepine 
binding site in the brain in multiple sclerosis: quantitative in vivo imaging of 
microglia as a measure of disease activity. Brain 2000; 123 ( Pt 11):2321-2337. 
 11 Cagnin A, Myers R, Gunn RG, Turkheimer FE, Cunningham VJ, Brooks DJ, 
Jones T, Banati RB. Imaging activated microglia in the ageing human 
  138 
brain. In: Physiological imaging of the brain with PET, Eds Gjedde, A , Hansen, S 
B , Knutsen, G, and Paulson, O B (2001) Academic Press, London 2001;361-365. 
 12 Gerhard A, Banati RB, Goerres GB, Cagnin A, Myers R, Gunn RN, Turkheimer F, 
Good CD, Mathias CJ, Quinn N, Schwarz J, Brooks DJ. [11C](R)-PK11195 PET 
imaging of microglial activation in multiple system atrophy. Neurology 2003; 
61(5):686-689. 
 13 Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Ogusu T, Torizuka T. 
Microglial activation and dopamine terminal loss in early Parkinson's disease. 
Ann Neurol 2005; 57(2):168-175. 
 14 American Psychiatric Association, 2000. Diagnostic and Statistical manual of 
Mental Disorders. 4th ed, text revision. Washington, DC: American Psychiatric 
Association. 
 15 Brix G, Zaers J, Adam LE, Bellemann ME, Ostertag H, Trojan H, Haberkorn U, 
Doll J, Oberdorfer F, Lorenz WJ. Performance evaluation of a whole-body PET 
scanner using the NEMA protocol. National Electrical Manufacturers Association. 
J Nucl Med 1997; 38(10):1614-1623. 
 16 Schuitemaker A, van Berckel BN, Kropholler MA, Kloet RW, Jonker C, Scheltens 
P, Lammertsma AA, Boellaard R. Evaluation of methods for generating 
parametric (R)-[11C]PK11195 binding images. J Cereb Blood Flow Metab 2007; 
27(9):1603-1615. 
 17 Hudson HM, Larkin RS. Accelerated image reconstruction using ordered subsets 
of projection data. IEEE Trans Med Imaging 1994; 13(4):601-609. 
 18 Maes F, Collignon A, Vandermeulen D, Marchal G, Suetens P. Multimodality 
image registration by maximization of mutual information. IEEE Trans Med 
Imaging 1997; 16(2):187-198. 
 19 West J, Fitzpatrick JM, Wang MY, Dawant BM, Maurer CR, Jr., Kessler RM, 
Maciunas RJ, Barillot C, Lemoine D, Collignon A, Maes F, Suetens P, 
Vandermeulen D, van den Elsen PA, Napel S, Sumanaweera TS, Harkness B, 
Hemler PF, Hill DL, Hawkes DJ, Studholme C, Maintz JB, Viergever MA, 
Malandain G, Woods RP. Comparison and evaluation of retrospective 
intermodality brain image registration techniques. J Comput Assist Tomogr 1997; 
21(4):554-566. 
 20 Svarer C, Madsen K, Hasselbalch SG, Pinborg LH, Haugbol S, Frokjaer VG, 
Holm S, Paulson OB, Knudsen GM. MR-based automatic delineation of volumes 
of interest in human brain PET images using probability maps. Neuroimage 2005; 
24(4):969-979. 
  139 
 21 Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of 
ligand-receptor binding in PET using a simplified reference region model. 
Neuroimage 1997; 6(4):279-287. 
 22 Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor 
studies. Neuroimage 1996; 4(3 Pt 1):153-158. 
 23 Turkheimer FE, Edison P, Pavese N, Roncaroli F, Anderson AN, Hammers A, 
Gerhard A, Hinz R, Tai YF, Brooks DJ. Reference and target region modeling of 
[11C]-(R)-PK11195 brain studies. J Nucl Med 2007; 48(1):158-167. 
 24 Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, Holden J, 
Houle S, Huang SC, Ichise M, Iida H, Ito H, Kimura Y, Koeppe RA, Knudsen GM, 
Knuuti J, Lammertsma AA, Laruelle M, Logan J, Maguire RP, Mintun MA, Morris 
ED, Parsey R, Price JC, Slifstein M, Sossi V, Suhara T, Votaw JR, Wong DF, 
Carson RE. Consensus nomenclature for in vivo imaging of reversibly binding 
radioligands. J Cereb Blood Flow Metab 2007; 27(9):1533-1539. 
 25 Debruyne JC, Versijpt J, Van Laere KJ, De Vos F, Keppens J, Strijckmans K, 
Achten E, Slegers G, Dierckx RA, Korf J, De Reuck JL. PET visualization of 
microglia in multiple sclerosis patients using [11C]PK11195. Eur J Neurol 2003; 
10(3):257-264. 
 26 Hutton C, Draganski B, Ashburner J, Weiskopf N. A comparison between voxel-
based cortical thickness and voxel-based morphometry in normal aging. 
Neuroimage 2009. 
 27 Tisserand DJ, van Boxtel MP, Pruessner JC, Hofman P, Evans AC, Jolles J. A 
voxel-based morphometric study to determine individual differences in gray 
matter density associated with age and cognitive change over time. Cereb Cortex 
2004; 14(9):966-973. 
 28 Bergfield KL, Hanson KD, Chen K, Teipel SJ, Hampel H, Rapoport SI, Moeller 
JR, Alexander GE. Age-related networks of regional covariance in MRI gray 
matter: reproducible multivariate patterns in healthy aging. Neuroimage 2010; 
49(2):1750-1759. 
 29 Chetelat G, Villemagne VL, Bourgeat P, Pike KE, Jones G, Ames D, Ellis KA, 
Szoeke C, Martins RN, O'Keefe GJ, Salvado O, Masters CL, Rowe CC. 
Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. 
Ann Neurol 2010; 67(3):317-324. 
 30 Conde JR, Streit WJ. Microglia in the aging brain. J Neuropathol Exp Neurol 
2006; 65(3):199-203. 
  140 
 31 Vehmas AK, Kawas CH, Stewart WF, Troncoso JC. Immune reactive cells in 
senile plaques and cognitive decline in Alzheimer's disease. Neurobiol Aging 
2003; 24(2):321-331. 
 32 Boellaard R., Turkheimer, F., Hinz, R., Schuitemaker, A., Scheltens, P., van 
Berckel, B. N., and Lammertsma, A. A. Performance of a Modified Supervised 
Cluster Algorithm for Extracting Reference Tissue Input Functions from (R)-
[11C]PK11195 PET Studies. IEEE Medical Imaging Conference Program 2008; 
IEEE Medical Imaging Conference Program:209-209 (M10-504). 
 33 Mourik JE, Lubberink M, van Velden FH, Kloet RW, van Berckel BN, 
Lammertsma AA, Boellaard R. In vivo validation of reconstruction-based 
resolution recovery for human brain studies. J Cereb Blood Flow Metab 2010; 
30(2):381-389. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  141 
Table 1: Mean (±SD) values of regional (R)-[11C]PK11195 BPND together 
with corresponding regression coefficients and correlation coefficient of linear 
regression analysis against age. 
ROI Mean BPND ± SD Regression 
coefficient ± SE  
 
Correlation 
coefficient 
Frontal  0.147 ± 0.081 0.002 ± 0.001* 0.470 
Anterior cingulate  0.122 ± 0.121 0.003 ± 0.001* 0.459 
Posterior cingulate  0.214 ± 0.123 0.004 ± 0.001* 0.600 
Superior temporal 0.141 ± 0.117 0.001 ± 0.001   0.177 
Medial inferior temporal  0.160 ± 0.101 0.003 ± 0.001* 0.711 
Insula 0.102 ± 0.160 0.005 ± 0.001*  0.617 
Hippocampus 0.041 ± 0.116 0.003 ± 0.001* 0.479 
Entorhinal -0.119 ± 0.148 0.003 ± 0.001* 0.487 
Thalamus 0.286 ± 0.111 0.004 ± 0.001* 0.740 
Parietal 0.127 ± 0.124 0.002 ± 0.001* 0.358 
Occipital 0.319 ± 0.155 0.003 ± 0.001* 0.458 
Sensory motor 0.128 ± 0.079 0.001 ± 0.001 0.190 
Cerebellum 0.212 ± 0.105 0.003 ± 0.001* 0.558 
Total brain 0.046 ± 0.171 0.000 ± 0.002 0.022 
BPND = binding potential; ROI = region of interest; SE = standard error. 
 *p < 0.05  
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Figure legend 
 
Figure 1: (R)-[11C]PK11195 BPND in posterior cingulate cortex as function of age. The 
linear regression line is shown.  
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Abstract 
Inflammatory mechanisms, like microglial activation, could be involved in the 
pathogenesis of Alzheimer’s disease (AD). (R)-[11C]PK11195, a PET ligand, can be 
used to quantify microglial activation in vivo. The purpose of this study was to assess 
whether increased (R)-[11C]PK11195 binding is present in AD and mild cognitive 
impairment (MCI), currently also known as “prodromal AD”. 
Methods Nineteen patients with probable AD, 10 patients with prodromal AD 
(MCI) and 21 healthy controls were analyzed. Parametric images of binding potential 
(BPND) of (R)-[
11C]PK11195 scans were generated using receptor parametric mapping 
(RPM) with supervised cluster analysis. Differences between subject groups were 
tested using mixed model analysis and associations between BPND and cognition were 
evaluated using Pearson correlation coefficients.   
Results Voxel-wise SPM analysis showed small clusters of significantly 
increased (R)-[11C]PK11195 BPND in occipital lobe in AD dementia patients compared 
with healthy controls. ROI based analyses showed no differences, with large overlap 
between groups. There were no differences in (R)-[11C]PK11195 BPND between 
clinically stable prodromal AD patients and those who progressed to dementia and 
BPND did not correlate with cognitive function. 
Conclusion Microglial activation is a subtle phenomenon occurring in AD.  
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Introduction  
Alzheimer’s disease (AD) is a neurodegenerative disorder, clinically characterized by 
progressive cognitive decline and impaired execution of daily activities.1 Patients with 
mild cognitive impairment (MCI) have documented memory impairment, but are still 
able to perform daily activities in a normal manner. MCI is considered to be a 
transitional phase between normal aging and AD.2 Subjects with MCI have an 
increased risk of developing clinical AD of about 12% per year compared with 1-2% in 
the general population.3 Recently, new criteria for the diagnosis of AD were proposed, 
which allows diagnosis related to neuropatholocial changes in AD, based on the use of 
biomarkers of AD.4 According to this new classification, patients with MCI are 
considered to have “prodromal AD”.  
AD is characterized histopathologically by intracellular neurofibrillary tangles 
(NFT), extracellular deposits of amyloid in senile plaques and diffuse loss of neurons.5 
Although not a pathological hallmark specific to AD, activated microglia invariably are 
found in AD and they may be present years before symptoms become apparent 
clinically.6 Indeed, activated microglia could be an important therapeutic target, as 
microglial activation may be directly involved in the neurodegenerative process 
associated with AD.7  
Microglial activation can be quantified in vivo using positron emission 
tomography (PET) and (R)-[11C]PK11195. (R)-PK11195 (1-(2-chlorophenyl)-N-methyl-
N-1(1-methylpropyl)-3-isoquinolinecarboxamide) is a highly specific ligand for the 
peripheral benzodiazepine binding site (PBR). This site, also called the translocator 
protein,8 is expressed by cells of the mononuclear macrophage lineage and is markedly 
increased in activated microglia. Using (R)-[11C]PK11195 and PET, microglial activation 
has already been demonstrated in several neurodegenerative diseases.9 In AD, 
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increased (R)-[11C]PK11195 binding has been found in several brain areas.10,11 
Recently, there have been two reports on (R)-[11C]PK11195 binding in MCI.12,13 In both 
studies (R)-[11C]PK11195 binding was assessed in two cohorts of MCI patients, being 
11C-labelled Pittsburgh Compound B ([11C]-PIB) positive and negative patients. These 
studies found either increased12 or unchanged13 (R)-[11C]PK11195 binding in MCI.  
 The purpose of the present study was to further investigate the extent and 
distribution of (R)-[11C]PK11195 binding in larger cohorts of AD dementia and 
prodromal AD patients. A second aim was to establish whether presence of activated 
microglia in prodromal AD is associated with progression to AD dementia.  
 
 
Methods 
Subjects 
Twenty patients with probable AD, 13 patients with MCI and 21 healthy controls were 
included. Patients were recruited from the outpatient clinic of the Alzheimer centre at 
the VU University Medical Center. All patients underwent standardized clinical 
assessment, including neurological and physical examinations, laboratory screening 
tests (including cerebrospinal fluid measures of amyloid β (Aβ), tau and tau 
phosphorylated at threonine-181),14 electro-encephalogram, magnetic resonance 
imaging (MRI) and neuropsychological examination. Final diagnosis was established at 
a multidisciplinary consensus meeting. Diagnosis of probable AD was based on 
NINCDS-ADRDA criteria,1 and diagnosis of MCI on Petersen criteria.2  Subjects 
underwent a standard battery of examinations, including history taking, medical and 
neurological examination, and neuropsychological examination, which consisted of the 
New York University Recall Test (NYU), Rey’s Auditory Verbal Learning Test (RAVLT), 
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Trail Making Test A and B, Fluency, Rey’s complex figure, Boston Naming Test and 
forward and backward condition of the Digit Span.  
According to recently proposed criteria for prodromal AD,4 MCI and AD patients 
were excluded from the analysis if there was no medial temporal lobe atrophy (MTA) or 
no abnormal cerebrospinal fluid profile14 (one MCI patient). Consequently, MCI will be 
reported as prodromal AD. For clinical follow-up, prodromal AD patients visited the 
memory clinic annually. One patient progressed to dementia with Lewy bodies and was 
excluded from the analyses.  
Controls without cognitive complaints were recruited by advertisement in local 
newspapers. All control subjects underwent the same diagnostic procedure (except 
EEG and lumbar puncture). Control subjects had to have age corrected normal scores 
on neuropsychological assessments and a normal MRI (including medial temporal lobe 
atrophy scores),14 which was evaluated by a neuroradiologist.   
Exclusion criteria for all subjects were known major psychiatric illness, previous 
head trauma with loss of consciousness of more than one hour duration, any significant 
metabolic disorder, and alcohol or substance abuse according to the DSM-IV criteria.15 
Intake of benzodiazepines, antipsychotic drugs and non-steroidal anti-inflammatory 
drugs was not allowed because of possible interaction with (R)-[11C]PK11195 binding. 
Written informed consent was obtained from all participants and in case of patients with 
AD also from a next of kin. The study protocol was approved by the Medical Ethics 
Review Committee of the VU University Medical Center. 
 
MRI 
All subjects had a structural MRI scan within four months of the PET procedure. MRI 
scans were acquired using a 1.0 T scanner (Magnetom IMPACT, Siemens Medical 
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Solutions, Erlangen, Germany) and included a 3D heavily T1-weighted gradient echo 
sequence (MP-RAGE). Voxel size of the MRI images was 0.98 x 0.98 x 1.49 mm. 
These scans were used both for segmentation of grey and white matter and for 
delineation of regions of interest (ROI).  
 
Production of (R)-[11C]PK11195  
(R)-[11C]PK11195 was produced according to published methods.16 Each (R)-
[11C]PK11195 injection solution met the following pharmaceutical specifications: 
specific activity >18.5 MBqmol-1; radiochemical purity >98 %; pH 5-8.  
 
PET 
PET scans were acquired using an ECAT EXACT HR+ (Siemens/CTI, Knoxville, TN, 
USA).17 First, a 10 minutes transmission scan was performed in 2D acquisition mode 
using three retractable rotating line sources. This scan was used to correct the 
subsequent emission scan for photon attenuation. Then, a 3D dynamic (R)-
[11C]PK11195 emission scan was performed consisting of 22 frames with progressive 
increase in frame duration (1 x 30 background, 1 x 15, 1 x 5, 1 x 10, 2 x 15, 2 x 30, 3 x 
60, 4 x 150, 5 x 300 and 2 x 600 s; total acquisition time 60.5 minutes). Detailed 
scanning procedures have been described previously.18-20 Subject motion during 
scanning was checked visually at regular intervals (by checking the position of the 
head using laser beams) and corrected immediately, if necessary.  
 
Image reconstruction  
All PET sinograms were corrected for dead time, tissue attenuation using the 
transmission scan, decay, scatter and randoms. Data were reconstructed using a 
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filtered back projection reconstruction (FBP) algorithm,21 as well as a partial volume 
corrected (PVC) ordered subset expectation maximisation (OSEM) reconstruction 
algorithm that incorporates the scanner’s point spread function in the system matrix 
during reconstruction. This PVC-OSEM algorithm has been validated previously.22 
Reconstructed images were filtered using a Hanning filter of 5 mm FWHM, both in 
transaxial and axial directions. A zoom factor of 2 and a matrix size of 256 x 256 x 63 
were used, resulting in a voxel size of 1.2 x 1.2 x 2.4 mm and a spatial resolution of 
approximately 2.5 mm full width at half maximum in the centre of the field of view. 
Images were then transferred to workstations (SUN Microsystems, Santa Clara, CA, 
USA) for further analysis. One AD and one prodromal AD patient were excluded 
because of insufficient quality of the PET scans for regional analyses (movement 
artefacts). 
 
 
Data analysis 
Parametric images of (R)-[11C]PK11195 PET scans were generated using receptor 
parametric mapping (RPM),23 a basis function implementation of the simplified 
reference tissue model (SRTM).24 RPM was found to be the most suitable parametric 
method for analysis of (R)-[11C]PK11195 scans.18 Supervised cluster analysis was 
used to extract the reference tissue input curve directly from the dynamic (R)-
[11C]PK11195 data.25 The primary outcome measure was binding potential (BPND).
24,26  
 
Regions of interest definition 
For each subject, PET and MRI scans were co-registered using the software package 
MIRIT.27,28 Regions of interest (ROI) were drawn manually on bilateral hippocampus, 
  151 
amygdala, entorhinal cortex, and lateral and superior temporal lobe using the software 
program DISPLAY (http://www.bic.mni.mcgill.ca/software/Display). In addition, template 
ROIs were defined using probability-map based automatic brain delineation.29 ROIs in 
this template include the frontal cortex (volume weighted average of superior frontal, 
orbital frontal and medial inferior frontal cortex), cingulate posterior cortex, thalamus, 
parietal cortex and occipital cortex. Regional values of BPND were obtained by 
projecting the manual and template ROIs, defined above, onto the parametric BPND 
images.  
 
Statistical analysis 
Statistical analyses of ROI data were performed using SPSS software (SPSS Institute, 
Chicago, Ill), version 15.0. Values are presented as mean ± standard deviation (SD). 
Differences in clinical characteristics, tracer doses and specific activity between 
different subject groups were tested using ANCOVA with post hoc Bonferroni 
corrections and age as a covariate. A linear mixed model was used to assess group 
differences in regional binding. Mixed models use all data available from all cortical 
regions, properly account for within-person correlations over the different cortical 
regions, and appropriately handle missing data. The model included diagnosis, region 
and interaction of diagnosis and region. Age was used as a covariate and BPND was 
the dependent variable. The threshold for significance was set at p < 0.05. Analyses 
were repeated with prodromal AD and AD combined as one patient group and 
compared to healthy control subjects. Associations between (R)-[11C]PK11195 binding 
and cognitive test results were evaluated using Pearson correlation coefficient adjusted 
for multiple comparisons.  
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Voxel-wise analysis 
Voxel-wise analysis of parametric BPND images was performed using Statistical 
Parametric Mapping (SPM) (SPM2; http://www.fil.ion.ucl.ac.uk/spm). The purpose of 
this analysis was to assess whether there were clusters of voxels with altered binding 
that could not be identified in the ROI analysis, for example due to heterogeneity within 
and across ROIs. As voxel-wise analysis is very sensitive to patient movement, scans 
were checked visually for motion artefacts prior to SPM analysis. Standard additional 
smoothing within SPM using a 10 mm full width at half maximum Gaussian filter was 
performed to reduce noise to acceptable levels and to obtain sufficient overlap of 
structures between subjects for SPM analysis. Differences between AD dementia or 
prodromal AD patients (and subgroups of (non)converters) and healthy controls were 
assessed in a voxel–wise comparison, using two sample t-tests. SPM analyses were 
performed without proportional scaling. Proportional scaling can be omitted because 
RPM plots are quantitatively accurate even at lower noise levels, as shown 
previously.30 SPM results were thresholded at both p < 0.01 and p < 0.001. The false 
discovery rate method to correct for multiple comparisons within SPM was used to 
provide corrected p-values.31  
 
 
Results 
Demographic and clinical data 
Baseline characteristics of participants, eligible for analysis, are presented in table 1. 
There were no differences in age or gender between AD patients, prodromal AD 
patients and healthy controls. MTA score was lower in healthy controls compared to 
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prodromal AD or AD dementia patients. AD dementia patients had lower MMSE scores 
than healthy controls and prodromal AD patients and scores in prodromal AD patients 
were lower than those in healthy controls. AD dementia patients and prodromal AD 
patients had lower scores on the NYU paragraph recall test, the RAVLT and the 
backwards condition of the digit span compared to controls. AD dementia patients had 
higher scores on the trail making test A compared to controls and prodromal AD, and 
on the trail making test B compared to controls. Seven of the 10 prodromal AD patients 
progressed clinically and fulfilled AD dementia criteria at follow-up. Three patients 
remained clinically stable until they were lost to follow up (mean follow-up duration was 
2.7 ± 0.5; range 2.3 – 3.3 years). Mean duration of follow-up for patients until 
converting to dementia was 2.6 years (SD = 1.6; range 1.1 – 5.8 years). Prodromal AD 
patients who converted to AD dementia had higher scores on the forward condition of 
the digit span than patients who did not convert (6.3 versus 4.7; p = 0.011). Otherwise, 
there were no differences in cognitive test results at baseline between converters and 
non-converters (p ≥ 0.05)). 
 
(R)-[11C]PK11195 administration 
There were no differences in injected tracer dose or specific activity between subject 
groups. Mean tracer dose was 350±102, 295±159 and 303±87 MBq (F(2,45) = 1.14, p 
= 0.33), and mean specific activity 79±36, 84±41 and 92±35 Gbqµmol-1 (F(2,47) = 
0.62, p = 0.54) in AD dementia patients, prodromal AD patients and healthy controls, 
respectively. Estimated receptor occupancy associated with these high SA tracer 
doses was < 1%.  
 
ROI analysis 
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In table 2 RPM derived BPND values of (R)-[
11C]PK11195 are shown for different brain 
regions in AD dementia patients, prodromal AD patients and healthy controls, using the 
standard FBP reconstruction algorithm. Linear mixed models showed no significant 
main effect of diagnostic group (p = 0.53). There was an effect of brain region (p < 
0.001). No interaction was found (p = 0.11), indicating that regional differences were 
similar across diagnostic groups. This is also illustrated in figure 1, showing BP values 
in the different subject groups. In general, BPND was highest in frontal lobe, posterior 
cingulate cortex, thalamus, parietal and occipital lobes. Results were similar (main 
effect of brain region (p < 0.001), but no main effect of diagnostic group (p = 0.93) and 
no interaction (p = 0.13)) when images with higher spatial resolution, as obtained with 
the PVC-OSEM reconstruction algorithm, were used.  
When the analyses were repeated, with prodromal AD and AD dementia combined as 
one patient group, comparable results were obtained.    
 
Voxel-wise analysis 
Voxel-wise analysis of BPND images showed increased (R)-[
11C]PK11195 binding in AD 
dementia patients compared with healthy controls in bilateral occipital cortex (p = 0.01) 
(Figure 2). At a higher statistical threshold (p = 0.001), no increased signal was found. 
No differences in (R)-[11C]PK11195 binding between prodromal AD patients (and 
subgroups) and healthy controls or AD dementia patients were found. When the 
analyses were repeated with prodromal AD patients and AD dementia patients as one 
group and compared to healthy control subjects no differences were found.  
 
(R)-[11C]PK11195 binding potential and cognition 
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There were no correlations with cognitive tests at baseline and (R)-[11C]PK11195 BPND 
in any region. There was no difference in BPND between prodromal AD patients who 
remained clinically stable and those who progressed clinically to dementia. 
 
 
Discussion 
In this study, only small clusters of increased (R)-[11C]PK11195 binding were found in 
bilateral occipital lobe in AD dementia patients using a voxel based analysis. ROI 
based analyses showed no differences between diagnostic groups, with large overlap 
between subject groups. This suggests that microglial activation in AD is a subtle 
phenomenon, which is present in AD dementia. 
Quantification of (R)-[11C]PK11195 specific binding (BPND) was performed using 
RPM18 and a modified supervised cluster analysis25,32,33 to extract the reference tissue 
input curve. Given the relatively low specific signal in AD and especially prodromal AD, 
it is essential to use optimal methodology. For quantification, use of a pure enantiomer, 
in this case (R)-[11C]PK11195, is mandatory.16 In addition, it has been shown that in 
pathological conditions like AD, with reduced flow rates or variations in blood volume, a 
basis function method is preferred above other simplified methods, such as 
standardised uptake values34 or (reference) Logan plot analysis,35,36 for analysing (R)-
[11C]PK11195 data because it produces less bias and is more precise.18 As such, RPM 
with an optimised supervised cluster analysis to extract the reference tissue curve was 
used in this study. 
The present findings are largely in agreement with previous (R)-[11C]PK11195 
studies in AD, in which cluster10 or supervised cluster analysis methods37 were used to 
derive the reference region and in which also subtle increased (R)-[11C]PK11195 
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binding was demonstrated. To date, two (R)-[11C]PK11195 studies in MCI patients 
have been reported.12,13 In both studies (R)-[11C]PK11195 binding was examined in 
[11C]PIB positive and negative patients, where [11C]PIB was used as a biomarker of  
disease severity. Wiley et al., reported (R)-[11C]PK11195 binding in cerebellum, mesial 
temporal cortex, sensorimotor cortex, frontal cortex, parietal cortex and posterior 
cingulate cortex but did not demonstrate significant differences between diagnostic 
groups13 comparable with the present results. Okello et al. did demonstrate increased 
(R)-[11C]PK11195 binding in the frontal cortex in a small group of [11C]-PIB positive 
patients, although no correlations between amyloid depositions, as measured with 
[11C]PIB, and (R)-[11C]PK11195 binding in frontal cortex were found.12  
In the present study only patients with the most common subtype of MCI, 
amnestic MCI, currently defined prodromal AD,2,4 were included. Neuropathological 
data indicate that many amnestic MCI patients have already high numbers of plaques 
and tangles,6,38,39 especially in the medial temporal lobe6,38 as has been acknowledged 
in the new proposed criteria for AD, in which patients with biomarker positive amnestic 
MCI are considered to have a predementia stage of AD (prodromal AD) 4. This is in 
agreement with post mortem studies demonstrating that activation of microglia 
precedes neurodegenerative changes in the neocortex.40,41 Indeed, a gradual increase 
of microglial activation with increasing Braak scores of neurofibrillary changes and with 
Congo red positive deposits has been reported.42,43 As clinicopathological and animal 
studies have demonstrated that microglia are attracted to the site of amyloid plaque 
formation,42,44 one could expect increased (R)-[11C]PK11195 binding in regions with 
reported Aβ deposition. Consequently, one might expect increased (R)-[11C]PK11195 
binding in prodromal AD patients, who progress to AD dementia, but also even earlier 
in preclinical AD. In this context, regional increases in (R)-[11C]PK11195 binding in 
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prodromal AD might reflect early changes, associated with Aβ deposition, occurring 
before structural changes can be seen. However, no differences in (R)-[11C]PK11195 
binding were found between prodromal AD patients who stayed stable and those who 
progressed to dementia.  
Moreover, although some trends were observed, none of the observed 
correlations with cognitive scores at baseline and (R)-[11C]PK11195 BPND in any of the 
brain regions in prodromal AD or AD dementia patients, were significant after 
correction for multiple statistical comparisons. Previously, Yokokura et al. examined 
(R)-[11C]PK11195 binding as well as [11C]-PIB and glucose metabolism in a relatively 
small group of AD patients and demonstrated a correlation between (R)-[11C]PK11195 
binding and MMSE scores in AD.11 Okello et al. also explored correlations between 
(R)-[11C]PK11195 binding and cognition in a small group of MCI patients and reported 
no correlations between (R)-[11C]PK11195 binding and MMSE in PIB-positive MCI 
patients12, which is in agreement with the present results. Because the sample size 
was relatively small and the follow-up period relatively short, a larger study is needed to 
confirm these findings. Furthermore, in order to assess (R)-[11C]PK11195 binding in the 
earliest stages of AD, it would also be interesting to study asymptomatic-at-risk or 
presymptomatic AD subjects.4 
Remarkably, ROI based analyses showed relatively low regional binding in the 
medial temporal lobe regions (figure 1). A negative BPND measure suggests that 
binding in the reference region is higher than that in the target region.  One could 
argue, however, that partial volume effects may have underestimated (R)-
[11C]PK11195 binding, especially in relatively small regions surrounded by 
cerebrospinal fluid, such as the hippocampus and entorhinal cortex, resulting in false 
negative binding. To limit partial volume effects, a novel PVC-OSEM reconstruction 
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algorithm was also applied, but this did not affect results. An alternative explanation 
could be that within an ROI a relatively smaller region shows increased (R)-
[11C]PK11195 binding. As such, averaging all voxels within a predefined ROI may dilute 
a potential signal in part of that ROI and could therefore lead to false negative findings. 
This might also explain the differences between voxel based and ROI based methods, 
as voxel based methods do not suffer from this “dilution”effect.  
The present results, describing only small areas with increased (R)-
[11C]PK11195 binding, suggest that microglia activation in AD is a subtle phenomenon. 
An important question is whether microglial activation plays a harmful or beneficial role 
in the development of AD. The function of microglia in the brain is twofold. In normal 
brain tissue they survey the brain environment and when structural or functional 
integrity of the brain is threatened they transform to activated states. When activated, 
microglia can have both neuroprotective and neurotoxic roles.45 As such, it is possible 
that activated microglia may induce neuronal damage. In AD, microglial activation 
occurs around neuritic plaques, where it may be involved in the degradation and 
phagocytosis of Aβ deposits.45 This could constitute a beneficial effect of microglia 
activation. Activated microglia, however, are also present in areas with low amyloid 
load, indicating that other mechanisms than plaque formation appear to contribute to 
microglia activation.46 Indeed, in an animal model of AD, microglial activation and loss 
of synapses preceded tangle formation,7 suggesting that microglial activation and 
neuronal damage are closely connected. Although preclinical studies do not provide 
conclusive evidence for either a neuroprotective or neurotoxic role of activated 
microglia in AD, converging data indicate that “inflammatory processes may be a 
driving force of the pathology associated with AD”.47 As such, neuroprotective 
strategies targeted at reducing microglial activity may be beneficial not only in AD 
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dementia, but also in prodromal AD. If microglial activation is a causative factor for 
neuronal degeneration, it could be an important target for treatment of age related 
cognitive problems. Imaging of microglial activation can contribute to better 
understanding of the role of inflammation in AD. It might also be useful to monitor the 
effect of future preventive and therapeutic treatments in clinical trials.  
In conclusion, small clusters of increased (R)-[11C]PK11195 binding were found 
in AD patients but not in prodromal AD subjects, indicating that microglial activation is a 
subtle phenomenon, present  in AD. Imaging of microglial activation may contribute to 
better understanding of the role of inflammation in AD.  
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Table 1: Subject Characteristics  
Data are represented as mean ± SD.  
AD = Alzheimer’s disease; MTA score = mean medial temporal lobe atrophy. MMSE = 
mini mental state examination. NYU = New York University paragraph recall test. 
RAVLT = Rey’s Auditory Verbal Learning Test. Trail A and B = trail making test A and 
B. Digit forward and backward = forward and backward condition of the digit span. 1) P 
< 0.05 for controls versus prodromal AD. 2) P < 0.05 for controls versus AD. 3) P < 0.05 
for prodromal AD versus AD. 
 
 
 
 Controls Prodromal AD AD 
N 21 10 19 
Age (years) 68  8 72  6 69  8 
Sex M : F 13 : 8 7 : 3 11 : 8 
MTA score 0.3  0.4 1.3  0.6 1.5  0.9 
MMSE 1, 2, 3   29  1 26  1 23  3 
NYU test score 1, 2 9.2  4.2 3.9   1.7 1.3   1.9 
RAVLT 1, 2 8.6  3.2 2.1  2.2  0.4  0.7 
Trail A 2, 3 4312 46 14 7122 
Trail B 2 8934 13968 19087 
Digit forward 6.40.9 5.81.0 6.11.0 
Digit backward 1, 2 5.71.1 3.70.5 4.51.2 
  166 
 
 
 
Table 2: Regional values of (R)-[11C]PK11195 BPND. 
ROIs Controls Prodromal AD AD 
Frontal  0.182 ± 0.101 0.202 ± 0.128 0.231 ± 0.127 
Cingulate posterior 0.370 ± 0.133 0.387 ± 0.142 0.338 ± 0.172 
Lateral temporal 0.054 ± 0.094 0.067 ± 0.111 0.079 ± 0.108 
Superior temporal 0.132 ± 0.141 0.136 ± 0.167 0.177 ± 0.092 
Amygdala  -0.103 ± 0.171 -0.167 ± 0.193 -0.054 ± 0.167 
Hippocampus  -0.049 ± 0.112 -0.032 ± 0.207 0.014 ± 0.120 
Entorhinal -0.156 ± 0.145 -0.080 ± 0.240 -0.047 ± 0.176 
Thalamus 0.234 ± 0.090 0.279 ± 0.168 0.311 ± 0.182 
Parietal 0.202 ± 0.124 0.234 ± 0.156 0.199 ± 0.134 
Occipital 0.439 ± 0.108 0.462 ± 0.054 0.427 ± 0.144 
Data are represented as mean ± SD.  
ROIs = regions of interest; AD = Alzheimer’s disease 
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Figure 1 
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Figure 1. (R)-[11C]PK11195 BPND in healthy controls, prodromal Alzheimer’s disease (AD) and AD dementia patients. ♦ = 
controls, ■ = patient with prodromal AD who remained clinically stable, □ = patients with prodromal AD who progressed to 
dementia, ▲ = AD dementia patients. 
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Figure 2. Regions with increased (R)-[11C]PK11195 BPND in Alzheimer’s disease 
dementia compared with healthy controls. Images were thresholded at p = 0.01. Extent 
threshold = 10 voxels. The colour bar indicates T values. Data were corrected for 
multiple comparisons using the false discovery rate method within SPM. 
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Summary and discussion 
 
Main findings 
The general objective of the work described in this thesis was to develop methods for 
quantitative in vivo assessment of brain inflammation in Alzheimer’s disease (AD). This 
is important as it may provide further insight in the role of inflammation in the 
pathophysiology underlying AD. In addition, it may serve as a (surrogate) marker for 
disease modifying agents that target brain inflammation. Two approaches were used: 
studies in blood and cerebrospinal fluid (CSF), and imaging studies using positron 
emission tomography (PET). In blood and CSF, the inflammatory markers C-reactive 
protein (CRP), interleukin-6 (IL-6), α1-antichymotrypsin (ACT) and serum amyloid P 
(SAP) were related to clinical stages of AD. Using PET, the focus was on regional in 
vivo assessment of activated microglia in cerebral tissue of patients with prodromal AD 
(i.e. mild cognitive impairment (MCI)) and AD dementia using (R)-[11C]PK11195, a 
highly selective ligand for the peripheral type benzodiazepine receptor (PBR), recently 
renamed as translocator protein 18 kDa (TSPO), which, in the brain, is upregulated in 
activated microglia cells.1 
 In the first part of this thesis the presence of inflammatory markers in serum and 
CSF of MCI and AD patients was examined. In the study described in chapter 2 higher 
CRP levels were found in both CSF and blood of MCI cases compared to AD patients 
even after adjustment for age, ApoE ε4 genotype and cardiovascular diseases. This 
difference remained present in MCI patients with a low-risk Aβ42/tau biomarker profile 
for AD after adjustment for ApoE ε4, cardiovascular diseases, white matter lesions and 
brain infarcts. CSF IL-6 levels were also significantly higher in MCI patients with a low-
risk CSF profile. No differences were found for ACT between MCI and AD patients. 
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Next, in chapter 3, it was investigated whether serum amyloid P (SAP) levels in CSF 
or serum reflect involvement of SAP at various stages of AD. Results showed that SAP 
levels in CSF seem to mirror accumulation of SAP in amyloid deposits in different 
stages of AD. Lower levels of SAP in CSF were associated with a twofold higher risk of 
progression to dementia, predominantly AD. Although a strong correlation between 
serum and CSF concentrations of SAP was found, serum levels of SAP did not 
discriminate between groups.  
The second part of this thesis is dedicated to in vivo assessment of activated 
microglia, which are known to be associated with inflammation of the brain.  Building on 
previous studies on the development of quantitative methods for measuring activated 
microglia using (R)-[11C]PK11195 and PET, first several methodological aspects of 
assessing (R)-[11C]PK11195 binding at the voxel level were evaluated. In chapter 4, 
the performance of various parametric methods was compared with the results of full 
compartmental analysis, which is considered to be the gold standard. Logan graphical 
analysis2 was found to be a robust and fast method for obtaining parametric volume of 
distribution (Vd , currently also abbreviated as VT) images of (R)-[
11C]PK11195. In 
addition, parametric reference tissue methods for measuring binding potential (BPND) 
were evaluated using cerebellum as reference region. In the end, one of the Ichise 
linearizations (ICH1),3 one of the basis function methods (RPM1)4, and Logan graphical 
analysis with reference tissue input (Reference Logan)5 provided reasonably accurate 
and precise estimates of BPND at normal flow rates, as compared with results of the 
simplified reference tissue model (SRTM).6 In addition, effects of blood volume and 
blood flow on the accuracy of reference tissue parametric methods were evaluated. 
Simulations suggested that RPM1 is the best method in case of reduced flow rates, as 
Reference Logan and ICH1 showed more bias than RPM1 under these conditions. In 
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chapter 5 performance of these plasma input (Logan)2 and reference tissue parametric 
(RPM)4 methods on the outcome of statistical parametric mapping (SPM) analyses of 
(R)-[11C]PK11195 binding in young and elderly subjects was evaluated. Results 
showed that parametric BP images without proportional scaling provided the most 
sensitive framework for determining differences in (R)-[11C]PK11195 binding between 
younger and elderly subjects. Vd images could only demonstrate differences in (R)-
[11C]PK11195 binding when analysed with proportional scaling due to intersubject 
variation in K1/k2 (rate constants of forward and reverse transport across the blood-
brain barrier) and/or global (whole brain) inter-subject differences in (R)-[11C]PK11195 
binding. 
Finally, (R)-[11C]PK11195 BPND was evaluated in healthy aging as well as in 
prodromal AD and AD dementia patients. In healthy control subjects and AD patients 
definition of a reference region can be difficult, as it requires delineation of an unknown 
region without microglial activation. Therefore, RPM1 in combination with supervised 
cluster analysis was applied to extract the reference tissue input function.7,8 In chapter 
6 increased BPND of (R)-[
11C]PK11195 was found in healthy aging in frontal lobe, 
anterior and posterior cingulate cortex, medial inferior temporal lobe, insula, 
hippocampus, entorhinal cortex, thalamus, parietal and occipital lobes, and cerebellum. 
Chapter 7 provides BPND of (R)-[
11C]PK11195 in prodromal AD and AD dementia 
patients. Small clusters of increased (R)-[11C]PK11195 binding were found in occipital 
lobe in AD dementia patients using a voxel based analysis. Region of interest analysis, 
however, showed no differences between diagnostic groups, with large overlap 
between subject groups. No correlations were found between cognitive tests at 
baseline and (R)-[11C]PK11195 BPND in any of the brain regions and there were no 
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differences in BPND between prodromal AD patients who remained clinically stable and 
those who progressed clinically to dementia.  
 
 
General Discussion 
Inflammatory proteins in Alzheimer’s disease 
Epidemiological, pathological and animal studies support the hypothesis that 
inflammatory mechanisms are involved in the pathogenesis of AD. Indeed, activated 
microglia cells and inflammatory cytokines, such as IL-6, are elevated in AD.9 
Immunopathological studies have shown that amyloid plaques are co-localized with a 
variety of inflammation related proteins, and clusters of activated microglia and reactive 
astrocytes.10-12 Interestingly, the presence of microglial activation in AD patients with 
low Braak scores suggests that inflammation is an early event in AD 
pathophysiology.13,14 The question remains, however, whether this inflammatory 
response is beneficial or detrimental. 
Population studies suggest that higher serum levels of inflammatory markers, 
such as CRP, IL-6 and ACT can predict cognitive decline or dementia.15-18 In chapter 
2.1, significantly higher CRP levels in both CSF and serum, and higher levels of IL-6 in 
CSF of MCI were found compared to AD patients. This supports the hypothesis that 
inflammation occurs early in the pathological cascade of AD. However, levels of CSF 
proteins should be interpreted cautiously, as levels of inflammatory proteins measured 
in CSF can be the result of local production, but also of diffusion across the blood-CSF 
barrier. Diffusion of proteins from blood into CSF is a non-linear process, strongly 
dependent on molecular size. No differences in albumin quotient (i.e. CSF/serum 
concentrations of albumin) between MCI and AD patients were found, suggesting that 
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blood-CSF barrier permeability is not different between the patient groups studied 
(chapter 2.1).19 A correction for interindividual variation in blood-CSF barrier integrity 
was performed using an index of inflammatory markers20 and albumin. No differences 
in inflammatory indexes between AD and MCI patients, corrected for albumin, were 
found, suggesting that blood-CSF barrier permeability is not different between the two 
patient groups. For CRP a relatively low index was found suggesting that most CRP in 
CSF originated from diffusion across the blood-CSF barrier, although some contribution 
by local production cannot be excluded. The (relatively) high ACT and IL-6 indexes 
suggest that these factors are (at least in part) produced locally, rather than being 
transported across the blood-CSF barrier. Particularly IL-6 levels, which were slightly 
higher in CSF than in plasma, are indicative for local intracerebral production.  
The amyloid associated protein SAP is normally produced at low levels in the 
brain. SAP synthesis, however, is upregulated in AD brain.21 In chapter 2.2 lower SAP 
levels were found in CSF of MCI patients who converted to AD. Hypothetically, these 
lower levels of SAP might be a consequence of Aβ-SAP binding in the brain, as it has 
been shown that SAP accumulates in Aβ plaques and binds to newly formed amyloid 
fibrils.22-24 These low levels of SAP in MCI further support the hypothesis that 
neuropathological changes occur long before patients fulfil clinical diagnostic criteria for 
AD. 
 
In vivo imaging of microglial activation 
At present, the isoquinoline (R)-[11C]PK11195 is the best characterized and most 
widely used radioligand for in vivo quantification of activated microglia. It binds to the 
peripheral benzodiazepine receptor binding site, which was recently renamed to 
translocator protein 18 kDa (TSPO).25 TSPO is a hydrophobic protein, primary located 
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in the outer mitochondrial membrane. Usually, low levels of TSPO are present in the 
brain and they are limited to glial cells (astrocytes and microglia).26 However, in 
response to neuronal damage a dramatic increase in TSPO levels can be found.27 
Quantification of TSPO as a measure of microglial activation has been performed in 
several neurodegenerative diseases, such as AD, Parkinson’s disease and multiple 
sclerosis, but also in traumatic brain injury.28-33 Although astrocytes also show high 
levels of binding of PK11195 in vitro, focally increased PK11195 binding primarily 
appears to be related to locally activated microglia. This is supported by in vivo studies 
using both microglial and astrocytic markers, which have demonstrated that the 
distribution pattern of increased PK11195 binding matches that of activated microglia 
rather than that of reactive astrocytes.34,35 
 Microglial cells are related to cells of the mononuclear lineage and are activated 
at a very early stage in response to brain injury, in which a rapid transformation of 
microglia from a resting to an activated state takes place.36,37 They proliferate and 
migrate to the sites of brain injury38 and release a variety of growth factors and 
inflammatory cytokines.9 They also upregulate different surface receptors, which are 
thought to regulate microglial activation. Normally, microglial activation subsides and 
cells reset to their resting state. However, the changes over time in AD are not clear, 
and further longitudinal studies are needed to elucidate the time course of activation. 
 
Microglial activation in aging 
Despite several studies on microglial activation in neurodegenerative diseases, 
relatively little is known about microglial activation in normal aging. In normal brain 
there are generally low levels of TSPO expression. In chapter 4.1,  increased (R)-
[11C]PK11195 BPND was found throughout several cortical and subcortical brain 
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regions, namely frontal cortex, anterior and posterior cingulate cortex, parietal and 
occipital cortex, thalamus and cerebellum. Age related increases were also found in 
various temporal regions: medial inferior temporal lobe, insula, hippocampus and 
entorhinal cortex. These results indicate that activated microglia appear in several 
temporal lobe structures during healthy aging, which is in agreement with post mortem 
studies.39,40 Interestingly, regional cerebral atrophy with aging has been described 
previously and includes prominent grey matter loss in frontal areas, but also in anterior 
cingulate cortex, temporal, parietal and subcortical areas, as well as in insula, which is 
consistent with increased binding of (R)-[11C]PK11195 in these areas.41,42 The clinical 
relevance of these findings, however, is not clear, Recently, it was hypothesized that 
microglia are subject to cell senescence (dysfunction), which implies that progressive 
microglia activation precedes neurodegeneration. In that case, neurodegenerative 
changes in AD may be the result of age related diminution of neuroprotective functions 
of microglia. In other words, when the supporting function of microglia cells falls away, 
neurons are more prone to neurodegenerative changes.43  
 
Microglial activation in AD 
In chapter 4.2, small clusters of increased (R)-[11C]PK11195 binding were found in 
occcipital lobe in AD dementia. Cagnin et al. were the first to report increased (R)-
[11C]PK11195 binding in AD.29 They also reported that increased (R)-[11C]PK11195 
binding precedes grey matter loss as seen on MRI, indicating that microglial activation 
is an early phenomenon in the course of AD. Recently, Okello et al. demonstrated 
increased (R)-[11C]PK11195 binding in the frontal cortex in [11C]PIB positive MCI 
patients, suggesting that microglial activation is mainly associated with amyloid plaque 
deposition.44 This has also been demonstrated with immunohistochemical studies.45 In 
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addition, it has been shown that microglia are attracted to the site of amyloid plaque 
formation.46 Despite increased (R)-[11C]PK11195 binding in frontal cortex mentioned 
above, no correlation between amyloid depositions, as measured with [11C]PIB, and 
(R)-[11C]PK11195 binding, could be demonstrated in MCI.44 
 This thesis (chapter 4.2) shows subtle increased (R)-[11C]PK11195 binding in 
AD dementia patients, indicating that microglial activation is present in AD. Based on 
post mortem studies demonstrating that activation of microglia precedes 
neurodegenerative changes in the neocortex10,47 one might expect increased (R)-
[11C]PK11195 BPND in prodromal AD, occurring before structural changes can be seen. 
However, no increased (R)-[11C]PK11195 binding was found in prodromal AD patients.  
Likewise, differences in BPND between prodromal AD patients who progress 
clinically to dementia and those who remain clinically stable might be expected as well. 
However, (R)-[11C]PK11195 BPND was not associated with clinical progression and 
there were no correlations between cognitive function at baseline and (R)-
[11C]PK11195 BPND in any of the brain regions (chapter 4.2), which is consistent with 
previous findings.44  
The function of microglia cells in AD remains a matter of debate. Whether 
activation states are beneficial or harmful is still not known. In vitro data demonstrate 
that activated microglia can cause neuronal damage and therefore may play a role in 
disease progression.48 In contrast, there is also increasing evidence that presence of 
microglia might be protective by mediating clearance of Aβ.49 It has been hypothesized 
that microglia cells function differently at different time points in the progression of AD. 
In early stages of AD they clear Aβ depositions, whereas in advanced stages they 
become dysfunctional and unable to clear all of the Aβ.49 
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The notion that activated microglia and other inflammatory mediators may 
contribute to the pathogenesis of AD resulted in treatment with anti-inflammatory drugs 
in order to reduce inflammatory reactions. Several epidemiological studies have shown 
that non-steroidal anti-inflammatory drugs (NSAIDs) may exert neuroprotective effects 
in AD.50-54,54-56 This has also been suggested by several retrospective case-control 
studies reporting a protective effect of NSAIDs in AD.57,58 Unfortunately, randomized 
clinical trials studying beneficial effects of NSAIDs in AD have been disappointing.59-61 
A possible explanation might be the long term use of NSAIDs in epidemiologic studies, 
which can not be achieved in randomized clinical trials. Other important factors might 
be the timing of anti-inflammatory treatment or their mode of action (classical NSAIDs 
versus newer agents with a more selective action against COX-2). Interestingly, there 
is preliminary evidence that celecoxib, a COX-2 inhibitor, has in vivo anti-inflammatory 
properties, that could be detected using (R)-[11C]PK11195 and PET.62 At present, no 
clinical studies have been performed to investigate the effects of COX-2 inhibitors in 
AD patients.  
   
Methodological considerations 
The human (R)-[11C]PK11195 PET studies, described in this thesis, were all analysed 
using validated tracer kinetic models with both plasma and reference tissue input 
functions. In chapter 3, results of various parametric methods were compared with 
those of full compartmental analysis, which is considered to be the gold standard. For 
all parametric reference tissue methods cerebellum was used as reference region and 
RPM14 was shown to be the most accurate parametric method for analysing (R)-
[11C]PK11195 data. The choice of a reference region can, however, be difficult in 
healthy controls and AD patients, as it requires delineation of a region devoid of 
  182 
microglial activation. To circumvent this problem, a cluster analysis technique can be 
employed to extract a reference tissue input function. Recently, Turkheimer et al. 
demonstrated that this supervised cluster analysis method provides a robust and 
reproducible quantitative assessment of (R)-[11C]PK11195 binding in the human brain.7 
This method may provide some practical advantages over the use of a plasma input 
curve as no arterial sampling is required, making studies less invasive and laborious. 
Therefore, more recently, this new supervised cluster analysis method was further 
optimised. 63 Kinetic analyses were performed using both simplified reference tissue 
method (SRTM) with non-linear regression and RPM1. RPM1, with and without blood 
volume correction, showed similar results compared to SRTM.63 Therefore, in chapter 
4, this new supervised cluster analysis method was used for extracting the reference 
tissue input function followed with RPM1 analysis to obtain quantitative parametric 
images of binding.   
Another important methodological issue in PET imaging is the effect of subject 
motion. Patient motion is a limiting factor, which may result in under- or overestimation 
of measured tracer binding. Although in the present studies data were analysed without 
applying motion corrections, the effects on the final results will be small, as data from 
patients who moved substantially were not included in the final analysis.  
Furthermore, quantification of PET studies may be affected by partial volume 
effects, resulting from the limited spatial resolution. To limit these partial volume 
effects, a PVC-OSEM reconstruction algorithm was used in the clinical studies 
described in chapter 4. This algorithm uses the scanner’s point spread function to 
significantly enhance the spatial resolution of reconstructed scans. This method was 
recently validated by Mourik et al. for the HR+ scanner,64 the scanner used in the 
present studies, resulting in an improvement in spatial resolution from approximately 
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4.1 – 7.8 mm FWHM to 2.3 – 3.4 mm FWHM.64,65 Nevertheless, some partial volume 
effects will remain. Consequently, it is likely that observed BPND values still 
underestimate both extent and magnitude of microglial activation and it might be 
hypothesized that in relatively small regions surrounded by cerebrospinal fluid a 
disproportionate underestimation of the true signal occurs.  
 
New microglia ligands 
Although in vivo imaging of microglial activation using (R)-[11C]PK11195 has provided 
important information in a variety of neurological disorders, the relatively high level of 
non-specific binding and associated low signal-to-noise ratio makes quantification of 
the signal difficult. Therefore, the development of new tracers with more favourable 
binding profiles is being pursued by many radiopharmaceutical research groups 
worldwide. Recently, a number of novel TSPO receptor ligands have been synthesized. 
[11C]DAA1106 (N-(2,5-dimethoxybenzyl)-N-(5-fluoro-2-phenoxyphenyl)-acetamide) is a 
ligand that binds selectively and with higher affinity to the TSPO receptor than (R)-
[11C]PK11195.66 In a recent study, Yasuno et al. demonstrated increased 
[11C]DAA1106 binding in various regions in a relative small number of subjects with 
AD.67 Data were thoroughly analysed using a metabolite corrected plasma input 
function, although no partial volume correction was applied. These first results in 
humans are encouraging, but further development and validation are highly needed. 
[11C]CLINME (2-[6-chloro-2-(4-iodophenyl)-imidazo[1,2-α]pyridine-3-yl]-N-ethyl-N-
methyl-acetamide) is another promising radioligand. In a rat model of local acute 
neuroinflammation it was demonstrated in vivo that [11C]CLINME has a good specific to 
non-specific binding ratio.68 The pyrazolopyrimidine, N,N-diethyl-2-[2-(4-
methoxyphenyl)-5,7-dimethyl-pyrazolo[1,5-α]pyrimidin-3-yl]-acetamide ([11C]DPA-713), 
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with a lower lipophilicity and higher selectivity, also has potential as a potent ligand for 
microglial activation studies, showing higher affinity and better signal-to-noise ratio than 
(R)-[11C]PK11195.69 Labelling with [18F] would make it an attractive ligand for 
widespread distribution and more options for clinical use. Therefore, an 18F-labeled 
derivative of DPA-713, [18F]DPA-714, has been synthesized and evaluated in rodents 
and normal male baboon.70-72 It was shown to have suitable in vivo properties with 
rapid brain uptake and high specificity for the TSPO receptor,70 although specific 
binding was much lower than that of [11C]DPA-713.71 [11C]PBR28 (N-(2-
methoxybenzyl)-N-(4-phenoxypyridin3-yl)acetamide is another ligand with lower 
liphophilicity than (R)-[11C]PK11195 and [11C]DAA1106, which has also favourable 
characteristics. First results were promising as high specific binding in monkey brain 
was found.73 However, it appeared that 10-14 percent of human subjects show no 
binding to [11C]-PBR28 due to a 10-fold lower affinity for PBR28 than in so-called 
binders.74,75 Subsequent quantitative analyses revealed three binding affinity patterns 
in human subjects, i.e. high-, median- and low-affinity binding patterns. Substantial 
differences were found between high-affinity, medium-affinity and low-affinity binders 
for the TSPO ligands PBR28, PBR06, DAA1106, DPA713 and PBR111.76 For (R)-
[11C]PK11195 no differences in selectivity were found, indicating that the expected 
BPND will be the same for the three groups. This makes (R)-[
11C]PK11195 still the 
tracer of choice for in-vivo assessment of activated microglia. Current research focuses 
on the development of a novel series of N1-methyl-(2-phenylindol-3-yl)glyoxylamides, 
amongst others.77 First results are promising, showing high affinity for all types of 
binders. Clearly, further studies are needed to establish whether these ligands are 
suitable for imaging of microglia activation in vivo in human subjects.  
  
  185 
Recommendations for future research 
This thesis shows that inflammatory markers in CSF as well as in vivo quantification of 
(R)-[11C]PK11195 as a measure of microglial activation reflect the involvement of 
inflammation in AD. The combination of CSF markers and in vivo imaging of (R)-
[11C]PK11195 binding was studied, aiming to better understand the neurobiological 
basis of the disease. At present, there is no ideal PET ligand for in vivo quantification of 
microglial activation. Despite its limitations, (R)-[11C]PK11195 still provides a useful tool 
to study neuroinflammation in vivo. Ultimately, the development of a TSPO ligand with 
a high specific signal could facilitate further exploration of the mechanisms involved in 
the pathogenesis of AD and may allow selection of patients eligible for treatment 
directed against inflammation, even at the stage of the earliest clinical manifestations. 
Furthermore, it might facilitate monitoring disease progression and evaluate 
individualised therapy with an anti-inflammatory agent.  
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Nederlandse samenvatting 
 
Ontsteking bij de ziekte van Alzheimer – in vivo kwantificatie 
 
Achtergrond 
De ziekte van Alzheimer is een neurodegeneratieve aandoening en de meest 
voorkomende vorm van dementie. Het is een aandoening welke gekenmerkt wordt 
door progressieve geheugenstoornissen, problemen met denken, handelen en taal en 
diverse neuropsychiatrische symptomen. De ziekte kenmerkt zich neuropathologisch 
door opeenhopingen in de hersenen van het eiwit amyloïd-beta (Aβ) en door 
neurofibrillaire tangles, bestaande uit tau-eiwit. Aβ neerslagen ontstaan al in een zeer 
vroeg pre-klinisch stadium. 
De diagnose ziekte van Alzheimer berust op internationale consensuscriteria, 
waarbij de diagnose met zekerheid pas te stellen is bij pathologisch-anatomisch 
onderzoek. Er zijn de laatste jaren diverse biomarkers ontwikkeld waarmee al in een 
vroeg stadium van de ziekte, tijdens het leven (ofwel in vivo), de structurele en 
moleculaire veranderingen in de hersenen, kunnen worden weergegeven. Voorbeelden 
van deze biomarkers zijn MRI markers, eiwitbepalingen in het hersenvocht en een 
positron emissie tomografie scan waarmee eiwitneerslagen gevisualiseerd kunnen 
worden ([11C]PIB-PET) .  
Mild cognitive impairment (MCI) is een verzamelnaam voor een klinische 
toestand waarbij patiënten stoornissen in het cognitief functioneren (meestal het 
geheugen) hebben, meer dan op basis van leeftijd en opleidingsniveau verwacht mag 
worden. Deze stoornissen zijn nog niet ernstig genoeg om aan de criteria voor 
dementie te voldoen. Patiënten met MCI hebben een verhoogd risico op de 
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ontwikkeling van de ziekte van Alzheimer (ongeveer 10 – 15% per jaar). Recent zijn 
nieuwe onderzoekscriteria ontwikkeld voor de ziekte van Alzheimer waarin biomarkers 
een rol spelen (Dubois et al.). Volgens deze criteria kan bij patiënten met MCI in 
combinatie met tenminste een afwijkende biomarker de diagnose ziekte van Alzheimer 
al gesteld worden.  
Naast plaques en tangles worden ook geactiveerde microgliacellen gevonden in 
de hersenen bij de ziekte van Alzheimer. Microglia zorgen voornamelijk voor het 
opruimen van ongewenst materiaal in de hersenen, zoals virussen, bacteriën en 
amyloïd. Er zijn echter ook aanwijzingen dat microglia cellen juist betrokken zijn bij de 
vorming van neerslagen van Aβ. Een hypothese is dat het Aβ eiwit zelf een lokale 
immuunreactie op gang brengt, hetgeen resulteert in de aantrekking en activatie van 
microglia cellen. Microgliacellen produceren vervolgens diverse inflammatoire en 
neurotoxische factoren (ontstekingseiwitten) welke deze pathologische cascade verder 
versterken. 
Positron emissie tomografie (PET) is een beeldvormende techniek welke het 
mogelijk maakt processen in het lichaam zichtbaar te maken door gebruik van een 
geringe hoeveelheid radioactieve stof. Bij het PET onderzoek zoals beschreven in dit 
proefschrift is gebruik gemaakt van een koolstof-11 gelabelde tracer, (R)-
[11C]PK11195, welke bindt aan geactiveerde microglia cellen. In het verleden zijn reeds 
enkele studies met (R)-[11C]PK11195 verricht bij patiënten met MCI  of de ziekte van 
Alzheimer, welke geen of verhoogde (R)-[11C]PK11195 binding in MCI of de ziekte van 
Alzheimer lieten zien. Deze inconsistente resultaten zouden te maken kunnen hebben 
met verschil in groepsgrootte, scan techniek of methodologie. Juiste kwantificatie is 
belangrijk, aangezien het visualiseren van microglia activatie met (R)-[11C]PK11195 
PET meer inzicht kan geven in het ziekteproces en mogelijk in de toekomst ook van 
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belang zou kunnen zijn bij het evalueren van therapieën gericht op preventie of 
vertraging van het ziekteproces.  
Naast amyloïd eiwit bestaan plaques ook uit andere ontstekingseiwitten welke 
betrokken zijn bij het ziekteproces. Voorbeelden van eiwitten welke betrokken zijn bij 
ontstekingsreacties in de hersenen zijn serum amyloïd P (SAP), interleukine-6 (IL-6) en 
acute fase eiwitten als C-reactive protein (CRP) en α1-antichymotrypsine (ACT). Deze 
eiwitten kunnen in het bloed en hersenvocht bepaald worden. Er zijn aanwijzingen dat 
deze eiwitten geassocieerd zijn met achteruitgang van de cognitieve functies. Het is 
dus van belang om verder te onderzoeken hoe inflammatoire processen betrokken zijn 
bij de ontwikkeling en het beloop van de ziekte van Alzheimer.  
 
Doel 
Het doel van dit proefschrift was om verschillende aspecten van inflammatie in 
veroudering en (vroege stadia van) de ziekte van Alzheimer te evalueren om zo meer 
inzicht te verkrijgen in het ontstaansmechanisme van de ziekte. Daartoe zijn twee 
benaderingen gebruikt:  
- Het meten van ontstekingseiwitten in serum en hersenvocht (hoofdstuk 2 en 3) 
- Het meten van microglia activatie met behulp van de PET tracer (R)-
[11C]PK11195 (hoofdstuk 4, 5, 6 en 7) 
 
Opzet 
Gedurende de afgelopen jaren zijn we bezig geweest met het verzamelen van 
gegevens voor deze studie. Hiertoe zijn gegevens van gezonde proefpersonen (zowel 
jongeren als ouderen), patiënten met milde cognitieve klachten en patiënten met de 
ziekte van Alzheimer verzameld. Bij een deel van de proefpersonen werd bloed en 
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hersenvocht, middels een ruggenprik, afgenomen. Het hersenvocht staat in direct 
contact met de hersenen en de meetresultaten hiervan zijn daardoor een goede 
afspiegeling van processen in de hersenen. Bij de studies beschreven in het tweede 
deel van dit proefschrift, werd bij de proefpersonen een (R)-[11C]PK11195 PET scan 
verricht welke een beeld geeft van de mate van activiteit van microgliacellen in de 
hersenen.  
 
Onstekingsmarkers in serum en hersenvocht 
In het eerste deel van het proefschrift werd de aanwezigheid van ontstekingsmarkers in 
serum en hersenvocht van gezonde controles, patiënten met MCI en de ziekte van 
Alzheimer onderzocht. Allereerst (hoofdstuk 2) hebben we onderzocht of de 
onstekingsmarkers IL-6, ACT en CRP vroeg bij het ziekteproces betrokken zijn. We 
vonden dat CRP verhoogd is in zowel hersenvocht als bloed van patiënten met MCI 
vergeleken met de ziekte van Alzheimer. Juist MCI patiënten met een zogenaamd laag 
risicoprofiel voor de ziekte Alzheimer bleken een verhoogd CRP te hebben. IL-6 in het 
hersenvocht was ook verhoogd in deze groep MCI patiënten met een laagrisicoprofiel. 
Er waren geen verschillen in ACT niveaus tussen MCI en Alzheimer patiënten. Deze 
bevindingen suggereren dat bij patiënten in een vroege fase van de ziekte 
inflammatoire processen aanwezig zijn.  
Vervolgens hebben we gekeken of SAP niveaus in het hersenvocht en serum 
iets zeggen over de verschillende stadia’s van de ziekte (hoofdstuk 3). SAP wordt 
normaliter in lage hoeveelheden in de hersenen aangetroffen. Echter de productie 
neemt toe tijdens het ziekteproces. Onze resultaten laten zien dat SAP niveaus in 
hersenvocht van MCI patiënten welke klinisch verslechterden en de ziekte van 
Alzheimer ontwikkelden lager waren dan van patiënten welke klinisch stabiel bleven. 
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Deze lage SAP waarden zouden het gevolg kunnen zijn van binding van SAP aan 
amyloïd in de hersenen waardoor er verlaagde hoeveelheden SAP in hersenvocht 
aanwezig zijn. SAP in het hersenvocht lijkt zo een goede weerspiegeling te zijn van de 
SAP niveaus in amyloïd plaques in de verschillende stadia van de ziekte.  
Deze bevindingen onderbouwen de hypothese dat al in vroege stadia, voordat 
patiënten klinisch dement zijn, neuropathologische veranderingen in de hersenen 
voorkomen en dat hierbij ontstekingsprocessen betrokken zijn. 
 
Kwantificatie van (R)-[11C]PK11195 binding 
Alvorens (R)-[11C]PK11195 binding in normale veroudering en de ziekte van Alzheimer 
te meten, hebben we diverse methodes om (R)-[11C]PK11195 binding te kwantificeren 
geanalyseerd (hoofdstuk 4 en 5). Voor de analyse van (R)-[11C]PK11195 PET scans 
zijn diverse analyse methodes beschikbaar. Met behulp van farmacokinetische 
modellen kunnen de uitkomstmaten (onder andere bindingspotentiaal) bepaald 
worden. Er wordt hierbij onderscheid gemaakt tussen twee soorten farmacokinetische 
modellen, te weten “plasma input”, waarbij gebruik wordt gemaakt van metingen in het 
arteriële bloed, en “reference tissue”, waarbij een referentiegebied zonder aantoonbare 
binding gebruikt wordt. In het algemeen wordt bij deze farmacokinetische modellen 
gebruik gemaakt van niet-lineaire regressie. Nadeel van deze niet-lineaire modellen is 
dat ze tijdsintensief en gevoelig voor ruis zijn. Er zijn ook lineaire methodes, welke veel 
sneller, minder gevoelig voor ruis, maar soms minder nauwkeurig zijn. Met deze, 
zogenaamde parametrische, methodes kunnen analyses op voxel niveau worden 
uitgevoerd. Eerst hebben we de resultaten van diverse parametrische methodes 
vergeleken met de resultaten van niet-lineaire regressie methodes (hoofdstuk 4). 
Zowel parametrische methodes gebaseerd op plasma input als op reference tissue 
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bleken accurate waardes te geven. De beste resultaten werden verkregen met een 
methode die “receptor parametric mapping” (RPM) wordt genoemd. Vervolgens 
hebben we (hoofdstuk 5) onderzocht welke parametrische methode de meest 
betrouwbare resultaten geeft bij analyses op voxel niveau: de methode gebaseerd op 
plasma input of de methode gebaseerd op reference tissue input. We vonden dat de 
RPM methode (reference tissue) de meest sensitieve methode is om verschillen in (R)-
[11C]PK11195  binding aan te tonen.  
 
Kwantificatie van (R)-[11C]PK11195 binding in normale veroudering en de ziekte 
van Alzheimer  
Uiteindelijk hebben we (R)-[11C]PK11195 binding geëvalueerd in gezonde 
proefpersonen en bij patiënten met de ziekte van Alzheimer. Bij normale veroudering 
(hoofdstuk 6) vonden we (R)-[11C]PK11195 binding in diverse hersenstructuren, te 
weten de frontaal kwab, anterieure en posterieure cingulaire cortex, mediale inferieure 
temporaal kwab, insula, hippocampus, entorhinale cortex, thalamus, parietaal en 
occipitaal kwab. Deze gebieden komen grotendeels overeen met regio’s waarvan 
bekend is dat er weefselverlies optreedt bij veroudering. In de temporaal kwab is 
eerder ook met pathologisch onderzoek aangetoond dat er bij normale veroudering 
microglia activatie optreedt. De klinische relevantie van deze bevindingen is echter nog 
niet duidelijk. Mogelijk worden neurodegeneratieve veranderingen in de hersenen 
voorafgegaan door dysfunctie van microglia cellen.  
Tenslotte hebben we (R)-[11C]PK11195  binding geëvalueerd bij patiënten met 
de ziekte van Alzheimer (hoofdstuk 7). Op voxel niveau werd een hogere (R)-
[11C]PK11195 binding gevonden in de occipitaal kwab bij patiënten met de ziekte van 
Alzheimer. Dit werd alleen gevonden bij patiënten met Alzheimer dementie, niet bij 
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patiënten welke nog niet voldeden aan de criteria voor dementie. Er bleek ook geen 
verschil te zijn in (R)-[11C]PK11195 binding tussen patiënten welke klinisch 
verslechterden en patiënten welke klinisch stabiel bleven. Vervolgens hebben we 
onderzocht of (R)-[11C]PK11195 binding geassocieerd is met de bevindingen bij 
neuropsychologisch onderzoek. Er bleek geen correlatie te zijn tussen (R)-
[11C]PK11195 binding en cognitief functioneren.  Concluderend blijken patiënten met 
milde cognitieve stoornissen geen hogere (R)-[11C]PK11195 binding te hebben. Deze 
resultaten bevestigen dat er sprake is van microglia activatie bij de ziekte van 
Alzheimer, maar dat dit slechts een subtiel fenomeen is.  
 
Conclusie 
Bovenstaande resultaten laten zien dat ontstekingsprocessen betrokken zijn bij de 
ziekte van Alzheimer. De aanwezigheid van ontstekingseiwitten in het hersenvocht van 
patiënten met milde cognitieve klachten suggereert dat deze processen in een vroeg 
stadium van de ziekte een rol spelen. Dit hebben we echter niet kunnen bevestigen 
met moleculaire beeldvorming van microglia activatie met behulp van (R)-
[11C]PK11195 PET bij patiënten met milde cognitieve stoornissen. Wel hebben we 
verhoogde (R)-[11C]PK11195 binding aangetoond bij patiënten met de ziekte van 
Alzheimer, hetgeen impliceert dat microglia activatie een rol speelt bij de ziekte van 
Alzheimer.   
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